



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 5/10, C12Q 1/68, A61K 38/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/29555</b> <b>(43) International Publication Date:</b> 25 May 2000 (25.05.00)
<b>(21) International Application Number:</b> PCT/US99/25361 <b>(22) International Filing Date:</b> 29 October 1999 (29.10.99)  <b>(30) Priority Data:</b> 09/195,379           17 November 1998 (17.11.98)   US 09/193,445           17 November 1998 (17.11.98)   US 09/258,689           26 February 1999 (26.02.99)   US  <b>(71) Applicant (for all designated States except US):</b> SELECTIVE GENETICS, INC. [US/US]; 11035 Roselle Street, San Diego, CA 92121-1204 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LAROCCA, David [US/US]; 1530 Calle Tulipanes, Encinitas, CA 92024 (US). BAIRD, Andrew [CA/US]; 5309 Via Papal, San Diego, CA 92122 (US). KASSNER, Paul [US/US]; 3912 Trust Way, Hayward, CA 94545 (US).  <b>(74) Agents:</b> CHRISTIANSEN, William, T. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHODS USING GENETIC PACKAGE DISPLAY FOR DETECTING AND IDENTIFYING PROTEIN-PROTEIN INTERACTIONS  <b>(57) Abstract</b> <p>A genetic package display system and methodology for probing protein-protein interactions that lead to cell transduction, selecting and/or identifying internalizing ligands, target cells and tissues which internalize known or putative ligands, and cell transduction facilitating peptides is provided. A ligand displaying genetic package that carries a selectable marker (e.g., reporter, selection, etc.) and presents a ligand on its surface is utilized to identify internalizing ligands, transduction facilitating peptides, and/or a variety of cells and tissue types for the ability to be successfully transduced by the ligand displaying genetic package.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# METHODS USING GENETIC PACKAGE DISPLAY FOR DETECTING AND IDENTIFYING PROTEIN-PROTEIN INTERACTIONS

## TECHNICAL FIELD

5                   This invention relates generally to genetic package display (*e.g.*, phage display), and in particular, to selection of ligands that bind to a cell surface receptor and internalize useful in gene therapy, screening, and in various methodologies. The methods described herein are also referred to as Ligand Identification Via Expression or "LIVE™".

## 10 BACKGROUND OF THE INVENTION

Bacteriophage expressing a peptide on its surface has been used to identify protein binding domains, including antigenic determinants, antibodies that are specifically reactive, mutants with high affinity binding, identify novel ligands, and substrate sites for enzymes. In its most common form, a peptide is expressed as a fusion protein with a coat protein of a filamentous phage. This results in the display of the foreign protein on the surface of the phage particle. Libraries of phages are generated that express a multitude of foreign proteins. These libraries are bound to a substrate or cell that presents the binding partner of interest. This screening process is essentially an affinity purification. Bound phage are recovered, propagated, and the gene encoding the foreign protein may be isolated and characterized. This technology is commonly referred to as "phage display."

Through a process called "biopanning," the specific phage carrying a peptide or protein that interacts with a protein or other moiety on a solid phase can be identified and isolated. However, in many applications, binding or binding affinity is not the sole critical parameter. For example, in gene therapy, a gene sequence needs to be introduced into a cell. In preferred methods, the gene sequence is targeted to particular cells by way of a ligand / cell surface receptor interaction. Thus, the ligand must not only bind to the cells but must also be internalized. A native ligand that is

internalized, when used in a system for gene therapy may not be efficiently internalized. For example, both FGF2 and EGF are internalizing ligands.

Phage libraries can be screened for potentially internalizing ligands by biopanning on live cells and rescuing internalized phage from the cells after stripping  
5 off externally bound phage (*e.g.*, acid elution). However, this method may result in recovery of undesired phage that bind very tightly or are only partially internalized. Moreover, phage that are internalized and subjected to proteases lose infectivity and can not be recovered. Accordingly, current methodologies are inadequate to determine the usefulness of ligands for gene therapy.

10 Further, identification of target cells or tissues that are able to internalize ligands and express a transgene would readily allow one to identify specific target cells for known or putative ligands as well as allow one to identify ligands for specific cell or tissue types. However, current methods of target cell identification are hampered by the same difficulties, as noted above, with regard to  
15 screening for internalizing ligands. Accordingly, current methodologies are inadequate to determine which cell or tissue types are useful targets for ligand mediated gene therapy.

Thus, current screening methods are inadequate for selecting peptide or protein ligands that bind to a cell surface receptor and internalize. The present  
20 invention discloses display methods that select peptide or protein ligands that internalize, and further provides other related advantages.

## SUMMARY OF THE INVENTION

Within one aspect of the present invention, a method of selecting internalizing ligands displayed on a genetic package is presented, comprising: (a)  
25 contacting a ligand displaying genetic package(s) with a cell(s), wherein the package carries a gene encoding a detectable product which is expressed upon internalization of the package; and (b) detecting product expressed by the cell(s); thereby selecting internalizing ligands displayed on a genetic package.

In another aspect, the invention provides a method of identifying an internalizing ligand displayed on a genetic package, comprising: (a) contacting one or more ligand displaying genetic packages with a cell(s), wherein each package carries a gene encoding a selectable marker which is expressed upon internalization of the package, (b) detecting the selectable marker expressed by the cell(s); and (c) recovering a nucleic acid molecule encoding an internalizing ligand from the cell(s) expressing the product, and thereby identifying an internalizing ligand displayed on a genetic package.

In yet another aspect, the invention provides a method of identifying an internalizing ligand displayed on a genetic package, comprising: (a) contacting one or more ligand displaying genetic packages with a cell(s), wherein each package carries a gene encoding a selectable product which is expressed upon internalization of the package, (b) incubating the cell(s) under selective conditions; and (c) recovering a nucleic acid molecule encoding an internalizing ligand from the cell(s) which grow under the selective conditions; thereby identifying an internalizing ligand displayed on a genetic package.

In yet another aspect, a method is provided for a high throughput method of identifying an internalizing ligand displayed on a genetic package, comprising: (a) contacting one or more ligand displaying genetic packages with a cell(s) in an array, wherein each package carries a gene encoding at least one detectable product which is expressed upon internalization of the package; and (b) detecting product(s) expressed by the cell(s) in the array, and thereby identifying an internalizing ligand displayed on a genetic package. In one embodiment, the ligand displaying package comprises a library of ligand displaying packages.

In another aspect, the present invention provides a method of identifying an internalizing ligand displayed on a genetic package, comprising: (a) contacting one or more ligand displaying a genetic packages with a cell(s), wherein each package carries a selectable marker which is detectable upon internalization of the package, (b) detecting the selectable marker internalized by the cells; and (c) recovering a nucleic acid molecule encoding an internalizing ligand from the cell(s)

carrying the selectable marker, thereby identifying an internalizing ligand displayed on a genetic package.

Within one aspect of the present invention, a method of selecting internalizing ligand/anti-ligand pairs is presented, comprising: (a) contacting a ligand displaying genetic package(s) with a cell(s), wherein the package carries a gene encoding a detectable product which is expressed upon internalization of the package; and (b) detecting product expressed by the cell(s); thereby selecting ligand/anti-ligand pairs.

In another aspect, the invention provides a method of identifying a ligand or anti-ligand of an internalizing ligand/anti-ligand pair, comprising: (a) contacting one or more ligand displaying genetic packages with a cell(s), wherein each package carries a gene encoding a detectable product which is expressed upon internalization of the package, and wherein the cell(s) expresses an anti-ligand-receptor fusion protein on its surface; (b) detecting product expressed by the cell(s); and (c) recovering a nucleic acid molecule encoding an internalizing ligand and/or a nucleic acid molecule encoding an internalizing anti-ligand from the cell(s) expressing the product, and thereby identifying a ligand or anti-ligand of a internalizing ligand/anti-ligand pair.

In yet another aspect, the invention provides a method of identifying a ligand or anti-ligand of an internalizing ligand/anti-ligand pair, comprising: (a) contacting one or more ligand displaying genetic packages with a cell(s), wherein each package carries a gene encoding a detectable product which is expressed upon internalization of the package, and wherein the cell(s) expresses an anti-ligand-receptor fusion protein on its surface; (b) incubating the cell(s) under selective conditions; and (c) recovering a nucleic acid molecule encoding an internalizing ligand and/or a nucleic acid molecule encoding an internalizing anti-ligand from the cell(s) which grow under the selective conditions; thereby identifying a ligand or anti-ligand of a internalizing ligand/anti-ligand pair.

In yet another aspect, a method is provided for a high throughput method of identifying a ligand or anti-ligand of an internalizing ligand/anti-ligand

interactions, comprising: (a) contacting one or more ligand displaying genetic packages with a cell(s) in an array, wherein each package carries a gene encoding at least one detectable product which is expressed upon internalization of the package; and (b) detecting product(s) expressed by the cell(s) in the array, and thereby identifying a ligand or anti-ligand of a internalizing ligand/anti-ligand interactions. In one embodiment, the array contains cells expressing a library of anti-ligand-receptor fusion proteins. In another embodiment, the ligand displaying package comprises a library of ligand displaying packages.

Within one aspect of the present invention, a method of identifying a target cell or tissue for internalizing ligands is presented, comprising: (a) contacting a library of ligand displaying genetic packages with a cell(s) or tissue(s), wherein each package carries a gene encoding a detectable product which is expressed upon internalization of the package; and (b) detecting product expressed by the cell(s) or tissue(s), and thereby identifying a target cell or tissue for internalizing ligands.

In another aspect, the invention provides a method of selecting an internalizing ligand for a selected target cell or tissue within a pool of target cells or tissues and identifying a target cell or tissue for the internalizing ligand, comprising: (a) contacting a library of ligand displaying genetic packages with a pool of cell(s) or tissue(s), wherein each package carries a gene encoding a selectable marker which is expressed upon internalization of the package; (b) detecting the selectable marker expressed by the cell(s) or tissue(s); and (c) recovering a nucleic acid molecule encoding an internalizing ligand from a selected set of cell(s) or tissue(s) within the pool expressing the product.

In yet another aspect, the invention provides a method of selecting an internalizing ligand for a selected target cell or tissue within a pool of target cells or tissues and identifying a target cell or tissue for the internalizing ligand, comprising: (a) contacting a library of ligand displaying genetic packages with a pool of cell(s) or tissue(s), wherein each package carries a gene encoding a detectable product which is expressed upon internalization of the package; (b) incubating the cell(s) or tissue(s) under selective conditions; and (c) recovering a nucleic acid molecule encoding an

internalizing ligand from a selected set of cell(s) or tissue(s) within the pool which grow under the selective conditions; thereby selecting internalizing ligands and identifying a target cell or tissue for the internalizing ligand.

In yet another aspect, a method is provided for a high throughput method of identifying target cells or tissues for internalizing ligands, comprising: (a) contacting a library of ligand displaying genetic packages with cells or tissue in an array, wherein each package carries a gene encoding at least one detectable product which is expressed upon internalization of the package; and (b) detecting product(s) expressed by the cells or tissue in the array; thereby identifying target cells or tissues for internalizing ligands. In one embodiment, the array contains a variety of cell types. In another embodiment, the method further comprises step (c), wherein the library is a library of ligand displaying bacteriophages that is repeatedly divided into subset pools and screened using steps (a) and (b) until a specific bacteriophage expressing an internalizing ligand is identified.

In yet additional embodiments a medicament for gene therapy is provided, comprising an internalizing ligand identified by the of the present invention. Also provided are anti-bacterial agents comprising an internalizing ligand identified by the methods of the present invention.

Also provided are methods for identifying transduction facilitating peptides, comprising: (a) contacting one or more ligand displaying a genetic packages with a cell(s), wherein each package displays a putative transduction facilitating peptide and a ligand known to internalize, and wherein each package carries a selectable marker which is detectable upon internalization of the package, (b) detecting the selectable marker internalized by the cells; and (c) recovering a nucleic acid molecule encoding an internalizing ligand from the cell(s) carrying the selectable marker, and thereby identifying an internalizing ligand displayed on a genetic package.

In related embodiments, the selectable marker is selected from reporter gene expression, expression of a gene that confers the ability to permit cell growth under selection conditions, non-endogenous nucleic acid sequences that permit PCR



amplification, and nucleic acid sequences that can be purified by protein/DNA binding.

In preferred embodiments, the ligand displaying genetic package comprises a bacteriophage. The bacteriophage are filamentous phage or lambdoid phage in other preferred embodiments. In some embodiments, the bacteriophage carries a genome vector. In other embodiments, the bacteriophage carries a hybrid vector.

In other embodiments, the library is a cDNA library, an antibody gene library, a random peptide gene library, or a mutein library. In other preferred embodiments, the detectable product is selected from the group consisting of green fluorescent protein,  $\beta$ -galactosidase, secreted alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, human growth hormone and neomycin phosphotransferase.

In other embodiments, the cells may be isolated by flow cytometry, for example. In further embodiments, the methods further comprise recovering a nucleic acid molecule encoding the ligand from the cell(s) expressing the product. Also provided are methods for enhancing transduction by utilizing genotoxic agents, heat shock, and transduction facilitating peptides.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth below which describe in more detail certain procedures or compositions (e.g., plasmids, etc.), and are therefore incorporated herein by reference in their entirety.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of phage vectors for mammalian cell transduction. Figure 1A depicts the parent phage vector with wild type pIII coat protein. The base vector is M13 genome with ampicillin resistance ( $\text{Amp}^R$ ) gene and GFP expression cassette inserted into the intergenic region between pIV and pII (MEGFP3). The MEGFP3 vector contains the following elements: ori-

CMV, SV40 replication origin and CMV promoter; EGFP, enhanced green fluorescent protein gene; BGH, and a bovine growth hormone polyadenylation sequence. Figure 1B represents the FGF-pIII fusion display phage (MF2/1G3).

Figure 2 is a scanned image of a Western Blot analysis representing  
5 detection of FGF2-pIII fusion protein in protein extracts from purified FGF2-phage (FGF2-MEGFP).

Figures 3A and 3B are bar graphs of ELISA detection of FGF2 on FGF2-phage. Figure 3A depicts the amount of phage protein detected using both the empty MEGFP3 (*i.e.*, MG3) vector and the FGF2 fusion construct (FGF2-MEGFP).  
10 Figure 3B depicts the amount of FGF2 detected on the phage having the fusion construct.

Figures 4A and 4B are bar graphs representing the transduction of COS cells by FGF2-phage.

Figure 5 is a bar graph representing the transduction of COS cells by  
15 peptide display phage.

Figure 6 is a scanned image of a Western Blot analysis representing detection of EGF-pIII fusion protein in protein extracts from purified EGF-phage.

Figure 7 is a bar graph representing the dose response of COS cells to various phage titers.

Figure 8 is a bar graph representing a time course analysis of various  
20 incubation times and the effect on transduction.

Figures 9A and 9B are bar graphs representing the specificity of transduction of COS cells by EGF-phage.

Figure 10 is a bar graph representing transduction specificity of a  
25 variety of human carcinoma cells.

Figure 11 is a scanned image of ethidium bromide stained gel electrophoretic analysis of products obtained by PCR amplification of pIII genes/pIII gene fusions following various rounds of selection.

Figure 12 is a vector map of an AAV-Phage hybrid genome vector.

Figure 13 is a vector map of an AAV-Phage hybrid phagemid vector.  
30

Figure 14 is a bar graph depicting the effects on transduction following genotoxic treatment and/or heat shock treatment of target cells.

Figure 15 is a bar graph representing the effects on transduction following display of an endosomal escape peptide.

5 Figure 16 is a bar graph displaying the combined effect of heat shock and display of an endosomal escape peptide on transduction.

Figure 17 is a vector map of a pUC-MG4 phagemid vector.

Figure 18 is a vector map of a pUC-MG4-38 dual display vector.

#### DETAILED DESCRIPTION OF THE INVENTION

10 As noted above, the present invention provides methods of using ligand displaying genetic packages to identify protein-protein interactions, ligands that bind and internalize or that to identify target cells and/or tissues for known or putative ligands and to identify transduction facilitating peptides. While it should be understood that a variety of ligand display methods may be utilized (*e.g.*, phage display, RNA-peptide fusions, and ligand displaying bacteria), the present invention  
15 uses bacteriophage ligand display to exemplify the various embodiments.

Briefly, in one embodiment of the present invention, a library of antibodies, cDNAs, or genes encoding random peptides is cloned into a coat protein of a ligand displaying genetic package (*e.g.*, gene III protein of filamentous phage) is  
20 utilized. The phage genome also contains an "expression cassette" encoding a transgene placed downstream from a cell promoter that is active in the cells to be infected (Figure 1A). The transgene is generally a selectable gene product and/or a detectable marker. Phage are contacted with test cells and expression of the transgene is monitored or selected. Phage that internalize will confer the phenotype of the  
25 transgene, such as drug resistance or expression of a fluorescing protein. The cells may be isolated on the basis of transgene expression. For example, when the transgene is a drug resistance gene, cells are grown in the presence of the drug, such that only those cells receiving and expressing the transgene are propagated. The

gene(s) that are fused with the coat protein and that promoted cell binding and internalization are recovered from the selected cells by a suitable method.

#### I. DISPLAY PACKAGES

5 A variety of ligand displaying genetic packages may be used within the context of the present invention. A "ligand displaying genetic package" as used herein, refers to any package which comprises a peptide/protein ligand and carries a nucleic acid molecule capable of detection, once internalized in the target cell. In one  
10 expressed upon internalization into the cell thereby allowing for detection of an internalized genetic package. In other embodiments, the ligand displaying genetic package may carry a nucleic acid molecule which allows for detection via PCR of unique sequences or by the ability of the internalized nucleic acid sequences to bind non-endogenous DNA binding proteins (e.g., nucleic acid sequence could comprise a  
15 lac operon, thereby allowing for lac repressor binding). Accordingly, display may be by a virus, RNA-peptide fusions, bacteriophage, bacteria, or similar system (See, Phage Display of Peptides and Proteins, pages 151-193, Kay (Ed.), *Academic Press*, San Diego, 1996). Preferred methods utilize bacteriophage. Such phage include the filamentous phages, lambda, T4, MS2, and the like. A preferred phage is a  
20 filamentous phage, such as M13 or f1. Accordingly, many illustrations, while exemplifying the use of phage, could also be performed with any ligand displaying genetic package.

Phage that present the foreign protein or peptide as a fusion with a phage coat protein are engineered to contain the appropriate coding regions. A  
25 variety of bacteriophage and coat proteins may be used. Examples include, without limitation, M13 gene III, gene VIII; fd minor coat protein pIII (Saggio *et al.*, *Gene* 152:35, 1995); lambda D protein (Sternberg and Hoess, *Proc. Natl. Acad. Sci. USA* 92:1609, 1995; Mikawa *et al.*, *J. Mol. Biol.* 262:21, 1996); lambda phage tail protein pV (Maruyama *et al.*, *Proc. Natl. Acad. Sci. USA* 91:8273, 1994; U.S. Patent No.  
30 5627024); f1 coat protein (WO 96/11947; DD 292928; DD 286817; DD 300652);  $\phi$ 29

tail protein gp9 (Lee, *Viol.* 69:5018, 1995); MS2 coat protein; T4 small outer capsid protein (Ren *et al.*, *Protein Sci.* 5:1833, 1996), T4 nonessential capsid scaffold protein IPIII (Hong and Black, *Virology* 194:481, 1993), or T4 lengthened fibrin protein gene (Efimov, *Virus Genes* 10:173, 1995); PRD-1 gene III; Q $\beta$ 3 capsid protein (as long as dimerization is not interfered with); and P22 tailspike protein (Carbonell and Villaverde, *Gene* 176:225, 1996). Techniques for inserting foreign coding sequence into a phage gene are well known (*see e.g.*, Sambrook *et al.*, *Molecular Cloning: A Laboratory Approach*, Cold Spring Harbor Press, NY, 1989; Ausubel *et al.*, *Current Protocols in Molecular Biology*, Greene Publishing Co., NY, 1995).

In the preferred filamentous phage system, a wide range of vectors are available (*see*, Kay *et al.*, *Phage Display of Peptides and Proteins: A Laboratory Manual*, Academic Press, San Diego, 1996). The most common vectors accept inserts in gene III or gene VIII. Furthermore, the foreign gene can be inserted directly into the phage genome or into a phagemid vector. Methods of propagation of filamentous phage and phagemids are well known.

Filamentous phage vectors generally fall into two categories: phage genome and phagemids. Either type of vector may be used within the context of the present invention. Many such commercial vectors are available. For example, the pEGFP vector series (Clontech; Palo Alto, CA), M13mp vectors (Pharmacia Biotech, Sweden), pCANTAB 5E (Pharmacia Biotech), pBluescript series (Stratagene Cloning Systems, La Jolla, CA), pComb3 and M13KE (New England Biolabs), and others may be used. One particularly useful commercial phagemid vector is pEGFP-N1, which contains a green fluorescent protein (GFP) gene under control of the CMV immediate-early promoter. This plasmid also includes an SV40 origin of replication to enhance gene expression by allowing replication of the phagemid to high copy number in cells that make SV40 T antigen.

Other vectors are available in the scientific community (*see e.g.*, Smith, in *Vectors: A Survey of Molecular Cloning Vectors and their Uses*, Rodriguez and Denhardt, eds., Butterworth, Boston, pp 61-84, 1988) or may be constructed

using standard methods (Sambrook *et al.*, *Molecular Biology: A Laboratory Approach*, Cold Spring Harbor, NY, 1989; Ausubel *et al.*, *Current Protocols in Molecular Biology*, Greene Publishing, NY, 1995) guided by the principles discussed below.

5           The source of the ligand (*e.g.*, gene, gene fragment, peptide encoding sequence, chemically conjugated peptide or protein, non-covalently conjugated peptide or protein) may be for example, derived from a cDNA library, antibody library or random peptide library. Alternatively, the ligand may be from a library of random or selective mutations of a known ligand. In an additional alternative, the  
10   ligand may be from a library of known receptor or cell surface binding agents. For example, the library may contain a subset of peptides known to bind the FGF or EGF receptor, but that have unknown gene delivery and expression characteristics (*i.e.*, transduction capacity).

          When a cDNA library is used, the starting cDNA is synthesized from  
15   mRNA isolated from the source tissue or cell line from which the desired ligand originates. cDNA is then amplified using primers containing sequences of appropriate restriction enzyme sites for insertion into the desired vector. Alternatively, commercially available cDNA libraries (*e.g.*, Clontech; Palo Alto, CA) may be amplified for insertion into the vector.

20           Similarly, libraries of antibody fragments can be made from mRNA isolated from the spleen cells of immunized animals (immunized for example with whole target cells or membranes) or subcloned from existing antibody libraries from immunized or naive animals. Random peptide encoding sequences are subcloned from libraries that are commercially available (New England Biolabs; MA) or can be  
25   synthesized and cloned using previously described methods (see, Kay *et al.*, *supra*).

          Phage display libraries of random or selective mutations of known ligands (referred to herein as a "mutein library") for improved gene delivery are performed in the same manner as described for screening random peptide libraries. Random mutations of the native ligand gene may be generated using DNA shuffling  
30   as described by Stemmer (*Nature* 370:389-391, 1994). Briefly, in this method, the

ligand is amplified and randomly digested with DNase I. The 50-300 base pair fragments are reassembled in an amplification performed without primers and using *Taq* DNA polymerase or similar enzyme. The high error rate of this polymerase introduces random mutations in the fragments that are reassembled at random thus  
5 introducing combinatorial variations of different mutations distributed over the length of the gene. Error prone amplification may alternatively be used to introduce random mutations (Bartell and Szostak, *Science*, 261:1411, 1993). The ligand may be mutated by cassette mutagenesis (Hutchison *et al.*, in *Methods in Enzymology* 202:356-390, 1991), in which random mutations are introduced using synthetic  
10 oligonucleotides and cloned into the ligand to create a library of ligands with altered binding specificities. Additional mutation methods can be used. Some additional methods are described in Kay *et al.*, *supra*. Further, selective mutations at predetermined sites may be performed using standard molecular biological techniques (Sambrook *et al.*, *Molecular Cloning : A Laboratory Manual*, Cold Spring Harbor  
15 Press, 1989).

If a cDNA library cannot be generated because, for example, the source of the desired ligand is not available or is unknown, random peptide libraries or a cDNA library from placenta may be used as a starting point for screening. Methods for construction of random peptide libraries may be found, for example, in  
20 Kay *et al.*, *supra*. Briefly, the random peptides are encoded by DNA assembled from degenerate oligonucleotides and inserted into one of the bacteriophage vectors described herein. Several different strategies may be used to generate random peptides or peptide encoding sequences. For example, triplets of NNN, wherein each N is an equimolar representation of all four nucleotides, will generate all 20 amino  
25 acids (as well as 3 stop codons). Alternative strategies use NN(G/T) and NN(G/C), which results in 32 codons that encodes all 20 amino acids and only 1 stop codon. Other strategies utilize synthesis of mixtures of trinucleotide codons representing all 20 amino acids and no stop codons. Once the oligonucleotides are synthesized, they are assembled as double strands by a variety of schemes, one of which involves  
30 synthesis of the complementary strand (see Kay *et al.*, *supra*).

In addition to the ligand/coat protein fusion, in one embodiment, the vector may contain a gene whose product can be detected or selected for. As referred to herein, a "reporter" gene is one whose product can be detected, such as by fluorescence, enzyme activity on a chromogenic or fluorescent substrate, and the like or selected for by growth conditions. Such reporter genes include, without limitation, green fluorescent protein (GFP),  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), luciferase, neomycin phosphotransferase, secreted alkaline phosphatase (SEAP), and human growth hormone (HGH). Selectable markers include drug resistances, such as neomycin (G418), hygromycin, and the like.

10           The marker gene is in operative linkage with a promoter. Any promoter that is active in the cells to be transfected can be used. The vector should also have a viral origin of replication and a packaging signal for assembling the vector DNA with the capsid proteins.

Most applications of the present invention will involve transfection of  
15   mammalian cells, including human, canine, feline, equine, and the like. However, several embodiments of the present invention utilize expression in non-mammalian cells (*e.g.*, fungal, yeast, bacteria, and plant). The choice of the promoter will depend in part upon the targeted cell type. Promoters that are suitable within the context of the present invention include, without limitation, constitutive, inducible, tissue  
20   specific, cell type specific, temporal specific, or event-specific, although constitutive promoters are preferred.

Examples of constitutive or nonspecific promoters include the SV40 early promoter (U.S. Patent No. 5,118,627), the SV40 late promoter (U.S. Patent No. 5,118,627), CMV early gene promoter (U.S. Patent No. 5,168,062), bovine  
25   papilloma virus promoter, and adenovirus promoter. In addition to viral promoters, cellular promoters are also amenable within the context of this invention. In particular, cellular promoters for the so-called housekeeping genes are useful (*e.g.*,  $\beta$ -actin). Viral promoters are generally stronger promoters than cellular promoters.

Additional promoters known and available to those of skill in the art  
30   may also be useful within the context of the present invention. For example, if



display packages are to be used to transduce yeast, a yeast promoter will be required and are available in the context of a number of commercially available vectors from a variety of sources including Clontech, (Palo Alto, CA), and Invitrogen (Carlsbad, CA). Further, if transduction of bacteria is of interest a number of bacterial vectors  
 5 are available of which most are derived from the pUC lineage. In addition, a variety of plant vectors and promoters are available, for example general descriptions of plant expression vectors and reporter genes can be found in Gruber *et al.*, "Vectors for Plant Transformation, in Methods in Plant Molecular Biology & Biotechnology" in Glich *et al.*, Eds. pp. 89-119, CRC Press, 1993. Promoters useful within the context  
 10 of the present invention include both constitutive and inducible natural promoters as well as engineered promoters. Such promoters may be obtained from plants, viruses, or other sources, and include, but are not limited to: those described herein such as the 35S promoter of cauliflower mosaic virus (CaMV). Typically, for plant expression vectors, suitable promoters include the 35S RNA and 19S RNA promoters  
 15 of CaMV (Brisson *et al.*, *Nature* 310:511, 1984; Odell *et al.*, *Nature* 313:810, 1985); the full-length transcript promoter from Figwort Mosaic Virus (FMV) (Gowda *et al.*, *J. Cell Biochem.* 13D: 301, 1989 and U.S. Patent No. 5,378,619) and the coat protein promoter to TMV (Takamatsu *et al.*, *EMBO J* 6:307, 1987). Alternatively, plant promoters such as the light-inducible promoter from the small subunit of ribulose bis-  
 20 phosphate carboxylase (ssRUBISCO) (Coruzzi *et al.*, *EMBO J* 3:1671, 1984; Broglie *et al.*, *Science* 224:838, 1984); mannopine synthase promoter (Velten *et al.*, *EMBO J* 3:2723, 1984) nopaline synthase (NOS) and octopine synthase (OCS) promoters (carried on tumor-inducing plasmids of *Agrobacterium tumefaciens*) or heat shock promoters, *e.g.*, soybean hsp17.5-E or hsp17.3-B (Gurley *et al.*, *Mol. Cell. Biol.* 6:559,  
 25 1986; Severin *et al.*, *Plant Mol. Biol.* 15:827, 1990) may be used. See PCT Publication WO 91/19806 for a review of a variety of known plant promoters which are suitable for use within the context of the present invention.

In preferred embodiments, the phage has an origin of replication suitable for the transfected cells. Viral replication systems, such as EBV ori and  
 30 EBNA gene, SV40 ori and T antigen, or BPV ori, may be used. Other mammalian

replication systems may be interchanged. As well, the replication genes may cause high copy number. Expression of therapeutic genes from the phage genome may be enhanced by increasing the copy number of the phage genome. In one method, the SV40 origin of replication is used in the presence of SV40 T antigen to cause several hundred thousand copy number. The T antigen gene may be already present in the cells, introduced separately, or included in the phage genome under the transcriptional control of a suitable cell promoter. Other viral replication systems for increasing copy number can also be used, such as EBV origin and EBNA.

As noted above, phagemid vectors may also be utilized in the practice of the present invention. Phagemid vectors are plasmid vectors that contain filamentous phage sequences and therefore can be packaged into phage particles when the complementing phage structural proteins are provided in trans by helper phage. In conventional phagemid systems both the phagemid and helper phage encode pIII coat protein. A combination of both wild type and pIII-fusion protein is displayed on the resulting phagemid particles with the phagemid encoding the pIII fusion and the helper encoding wild type pIII. This results in a monovalent display of peptides or proteins with often less than one recombinant pIII fusion protein displayed per phage particle. Many antibody libraries are made in phagemid vectors because monovalent display is advantageous for selecting high affinity antibodies over lower affinity antibodies which in a high valence system might be selected on the basis of avidity. While similar concerns may justify the use of monovalent display vectors in the practice of the present invention, current data suggests, however, that multivalent display is important for mammalian cell internalization. (Larocca *et al.*, *FASEB J.* 13:727-734, 1999; Larocca *et al.*, *Human Gene Therapy* 9:2393-2399, 1998; Becerril *et al.*, *Biochem. Biophys. Res. Comm.* 255:386-393; Ivanenkov *et al.*, *Biochim. Biophys. Acta* 1448:450-462, 1999). Thus, a phagemid vector with multivalent display would likely be more useful for selecting internalizing phage in mammalian cells.

Multivalency in a phagemid system may be provided by rescuing with helper having a gIII deletion (or gVIII deletion, depending on the phagemid).

Accordingly, rescuing with a gIII deleted helper can alter the valency of phagemid vectors. Rakonjac and colleagues have developed host strains which allow production of the gIII deleted helper phage with very low background of gIII containing recombinants (as low as 1 in  $10^9$ ). See, *e.g.*, Rakonjac *et al.*, *Gene* 198:99-103, 1997. In this system there is little or no wild type pIII provided by the helper phage so that each phage displays multiple copies of the pIII fusion derived from the phagemid. Thus, in one embodiment the present invention utilizes a vector containing the EGF-pIII fusion protein from the phage vector, MG4-EGF (the vector MG4 is constructed by reversing the orientation of the SV40ori/CMV/GFP expression cassette in the MEGFP3 (MG3) phage vector. MG4-EGF has the EGF encoding gene inserted "in-frame" at the pst1/Nco1 sites in MG4) and similarly the control vector containing the CMV/SV40ori/GFP cassette and the pIII gene from the control phage. The pIII genes are under the transcriptional control of the inducible lac promoter to minimize synthesis of pIII protein in the absence of a suitable inducer (i.e. IPTG).

Construction and utilization of multivalent phagemid vectors is within the knowledge of those of skill in the art. Briefly, the backbone of the above phagemids can be easily constructed from pUC119 (purchased from ATTC) which contains an M13 phage origin of replication and an ampicillin resistance gene. The CMV/SV40ori/GFP gene is PCR amplified using primers that incorporate an AflIII endonuclease site and is inserted into the unique AflIII site in pUC119 to create pUC-GFP. The pIII and EGF-pIII fusion genes are subcloned from MG4 and MG4-EGF by PCR amplification using primers that encode HindIII and EcoRI endonuclease sites and insertion into pUC-GFP at the unique HindIII and EcoRI sites in the multicloning site to create pUC-MG4 (Figure 17) and pUC-MG4-EGF. The phagemid DNA constructs are used to transform host bacteria (XL-1 Blue; Stratagene, San Diego, CA) that contain the lac IQ repressor protein gene to suppress expression of the pIII or EGF-pIII fusion gene in the absence of IPTG. Phagemid particles are rescued from transformed bacteria with a wild type helper phage (i.e. R408 or VCSM13) or a gIII deleted helper (i.e. R408d3 or VCSM13d3, Stratagene,

San Diego, CA) and tested on COS1 cells for phage mediated transduction efficiency as measured by % GFP positive cells. The results of these experiments (not shown) indicate that the multivalent phage (VCSM13d3 rescued) are about 2 orders of magnitude more efficient at transducing COS1 cells than the monovalent display phagemid particles (wild type rescued). Western blot analysis (not shown) of CsCl  
5 phagemid particles reveals that about 50% of the pIII protein displayed on the VCSM13d3 rescued phagemid particles is fused to EGF; the remaining pIII protein is likely derived from a proteolytic cleavage of the fusion protein. Analysis of the  
10 monovalent phagemid particles shows that more than 66% of the displayed pIII is length of wild type pIII and of MG4-EGF phage shows that 60-80% of the pIII displayed is full length. Accordingly, such data demonstrate that multivalent display of the targeting ligand facilitates uptake of the ligand targeted phage via cognate receptor mediated endocytosis and that it is feasible to construct and use a multivalent phagemid system for phage mediated mammalian cell transduction.

15 In yet further embodiments, ligand fusions to a truncated pIII or pVIII gene may be utilized. Several advantages become apparent when expressing displayed ligands as fusions to a truncated pIII (or pVIII) gene. For example, rescue by helper phage is simplified because there is no interference of phagemid derived pIII with the infection by helper phage. Thus multivalent phagemid yields will likely  
20 be increased by infection with helper phage after induction of the phagemid pIII fusion gene (not possible with fusions to full length pIII because of interference). Additionally some ligands may be more efficiently expressed as a fusion to truncated pIII.

Phagemid vectors having truncated fusions to pIII or pVIII are easily  
25 produced by those of ordinary skill in the art. Briefly, a phagemid vector is created with a pIII gene having only domain 2 of pIII (preferably starting from amino acids 198-250 and ending at amino acid 406), as described by Dottavio (in Phage Display of Peptides and Proteins, Kay et al. (Eds.) San Diego, Academic Press, 1998). When this phagemid is rescued with the R408d3 or VCSM13d3 helper phage the resulting  
30 phagemid particles are no longer infective in bacteria since domain 1 of pIII is

required for infectivity. However these particles can be used for non-bacterial cell transduction and subsequent rescue of ligand encoding sequences as described herein. Further, to enhance ligand recognition it may be beneficial to fuse the sequence encoding the peptide or protein ligand or the peptide or protein ligand itself to domain

5 2 of pIII via a linker molecule (e.g., gly<sub>4</sub>ser, heterobifunctional linkers, and the like).

In a further embodiment, a viral replication system such as an SV40 based shuttle vector can be used as the phagemid. Accordingly, cells infected by the

ligand-expressing phage package the phagemid DNA into SV40 viral particles.

These viral particles infect neighboring cells, thus spreading the phagemid DNA.

10 Following growth in culture, a dish of cells contains millions of copies of the original phagemid, thereby enriching the population of internalized ligand encoding genetic packages several fold. The cell lines used with such a system can either be

transfected with DNA sequences encoding SV40 small and large T-antigens or can contain the proteins through delivery with fusion constructs, such as VP22. VP22 is a

15 herpes virus structural protein that is exported from cells and spreads to neighboring cells where it concentrates in the nucleus (Elliot and O'Hare, *Cell* 88:223-233, 1997).

VP22-SV40 T antigen fusion protein encoding vectors exist in the art and are available from Invitrogen Corp., as the pVP22myc-His vector. The vector useful in

this application ideally contains an f1, M13 or comparable phage origin, a coat

20 protein fusion cassette (pIII or pVIII), the SV40 late region genes, and an SV40 origin..

Similarly, an adeno-associated virus/phage hybrid vector may be used to achieve the same amplified ligand production. An AAV-phage hybrid vector

combines selected elements of both vector systems, providing a vector that is simple

25 to produce in bacteria that is not constrained by a capsid packaging limit, while allowing infection of quiescent cells combined with integration into the host chromosome. Vectors containing many of the appropriate elements are readily

available, and can be further modified by standard methodologies to include the necessary sequences. For example, the phagemid pAAV/Svneo, ATCC Accession

30 No. 68065, contains AAV ITR sequences and an F1 origin of replication. In addition

the vector pAV.CMV.LacZ provides many of the appropriate elements Fisher *et al.*, *J. Virol.* 70(1):520-532, 1996.

Adeno-associated virus (AAV) is a defective member of the parvovirus family. The AAV genome is encapsulated as a single-stranded DNA molecule of plus or minus polarity (Berns and Rose, *J. Virol.* 5:693-699, 1970; Blacklow *et al.*, *J. Exp. Med.* 115:755-763, 1967). Strands of both polarities are packaged, but in separate virus particles (Berns and Adler, *Virology* 9:394-396, 1972) and both strands are infectious (Samulski *et al.*, *J. Virol.* 61:3096-3101, 1987). The single-stranded DNA genome of the human adeno-associated virus type 2 (AAV2) is 4681 base pairs in length and is flanked by inverted terminal repeated sequences of 145 base pairs each (Lusby *et al.*, *J. Virol.* 41:518-526, 1982; Muzyczka, *Curr. Top. Microbiol. Immunol.* 158:97-129, 1992). In addition, the viral rep protein appears to mediate non-homologous recombination through the ITRs (Giraud *et al.*, *J. Virol.* 69:6917-6924, 1995; Linden *et al.*, *Proc. Natl. Acad. Sci. USA* 93:7966-7972, 1996). Accordingly, as parvoviral genomes have ITR sequences at each end which play a role in recombination and which are generally required for parvoviral replication and packaging, the vectors of the present invention generally contain all or a portion of at least one of the ITRs or a functional equivalent thereof.

Adeno-associated viruses may be readily obtained and their use as vectors for gene delivery has been described in, for example, Muzyczka, *Curr. Top. Microbiol. Immunol.* 158:97-129, 1992; U.S. Patent No. 4,797,368, and PCT Application WO 91/18088. Construction of AAV vectors is described in a number of publications, including U.S. Patent No. 5,173,414; Lebkowski *et al.*, *Mol. Cell. Biol.* 8:3988-3996, 1988; Tratschin *et al.*, *Mol. Cell. Biol.* 5(11):3251-3260; Hermonat and Muzyczka, *Proc. Nat'l. Acad. Sci. USA* 81:6466-6470, 1984; U.S. Patent Nos. 5,871,982, 5,773,289, 5,843,742, and 5,474,935; and PCT Application Nos. WO 98/45462 and WO 98/48005, all of which are incorporated herein by reference.

AAV-2 can be propagated as a lytic virus or maintained as a provirus, integrated into host cell DNA (Cukor *et al.*, in "The Parvoviruses," Berns ed., Plenum Publishing Corp., N.Y. pp. 33-66, 1984). Although under certain conditions AAV

can replicate in the absence of helper virus (Yakobson *et al.*, *J. Virol.* 61:972-981, 1987), efficient replication requires coinfection with either adenovirus (Atchinson *et al.*, *Science* 194:754-756, 1965; Hoggan, *Fed. Proc. Am. Soc. Exp. Biol.* 24:248, 1965; Parks *et al.*, *J. Virol.* 1:171-180, 1967); herpes simplex virus (Buller *et al.*, *J. Virol.* 40:241-247, 1981) or cytomegalovirus, Epstein-Barr virus, or vaccinia virus. Hence the classification of AAV as a "defective" virus.

The AAV-phage hybrid vector for ligand identification generally comprises an F1, M13 or comparable origin, a coat protein fusion cassette (*e.g.*, pIII-ligand or pVIII-ligand), a bacterial gene which facilitates selection, such as ampicillin resistance, and the two AAV ITRs (or functional equivalents thereof), between which is inserted the promoter driven reporter or selectable gene. The hybrid phage can then be used to transduce cells. The positive cells are identified and the ligand sequences are amplified by PCR using the ITRs or coat protein gene as the template sequence. This amplified ligand fusion construct can then be sub-cloned into other vectors for further rounds of transfection, selection, and ligand sequence identification.

In related embodiments, the present invention provides an AAV-phage vector that is designed to produce functional AAV viral particles upon co-infection with a "rescue" virus, such as an adenovirus. In this embodiment, the AAV-phage particle enters the cell as a "phage particle", but once inside, produces AAV particles that infect surrounding cells. This method can thus be used to amplify gene delivery effectiveness in a target organ or tissue. Briefly, in this approach, a ligand displaying phage particle containing a AAV-phage vector which contains a transgene of interest as well as ligand fused to the pIII or pVIII coat protein is used to transduce a cell. Concurrent with or subsequent to contacting the cells with the transgene containing AAV-phage particle, a ligand displaying helper AAV-phage is also used to supply the rep and cap genes for viral particle formation. Following transduction with the appropriate bacteriophage, the cell is infected with a "rescue" virus, such as an adenovirus, which allows viral particles to form and infect neighboring cells. Alternatively, the rep and cap functions can be supplied on the helper adenoviral genome.

In another aspect, mutant coat proteins or additional components or methods may be used to increase transduction efficiency. A particularly preferred manipulation is to mutagenize a coat protein so as to facilitate uncoating upon cellular internalization. For example, the filamentous phage coat protein VIII encoding gene  
5 can be mutagenized such that it encodes a slightly unstable protein and thus allows more rapid uncoating and increased transduction capacity. Accordingly, one of ordinary skill in the art would readily recognize that given the teachings presented herein that mutations may be selected for using reporter gene expression.

In the various embodiments, when utilizing filamentous phage or  
10 another single-stranded DNA vector, transduction may be enhanced by facilitating the conversion of the single-stranded DNA to double-stranded DNA. The mechanism for conversion of single-stranded phage DNA to double-stranded DNA is analogous to that which occurs during infection with single-stranded DNA genome of a parvovirus such as an adenoassociated virus (AAV). In the case of recombinant AAV,  
15 conversion to dsDNA is a rate-limiting step for efficient transduction. The E4 orf6 gene product provided by helper Adenovirus or on a separate expression plasmid provides this function and increases transduction efficiency between 100-1000 fold. Accordingly, as variety of genotoxic treatments including gamma radiation, UV, heat shock, and DNA synthesis inhibitors and topoisomerase inhibitors (*e.g.*, hydroxyurea,  
20 camptothecin, etoposide, and the like, *see, e.g.*, Ferrari *et al.*, *J. Virol.* 70:3227-3234, 1996; Alexander *et al.*, *J. Virol.* 68:8282-8287, 1994; Russell *et al.*, *PNAS* 92:5719-5723, 1995) will increase rAAV transduction efficiency in the absence of infection by helper virus, similar treatments can also increase the transduction efficiency of recombinant phage vectors and thus may be utilized in the practice of the present  
25 invention.

In other embodiments, peptides or other moieties that allow or promote the escape of the vectors (and any molecule attached thereto or enclosed therein) from the endosome are incorporated and expressed on or attached to the surface of the of the ligand displaying genetic package (*e.g.*, bacteriophage). Such  
30 "other moieties" include molecules that are not themselves peptides but which have



the ability to disrupt the endosomal membrane, thereby facilitating the escape of the vector, and molecules that otherwise mimic the endosomal escape properties of the within-described peptide sequences (*see, e.g.*, published PCT Application No. WO 96/10038, the disclosure of which is incorporated by reference herein).

5                   Peptide sequences that confer the ability to escape the endosome are particularly preferred. Such sequences are well known and can be readily fused or conjugated covalently or genetically to a coat protein, such as gene III or gene VIII of filamentous phage. Although fusion of one or more peptide sequences to a coat protein is described herein as a preferred embodiment, it should be understood that  
10 other methods of attachment -- and other moieties besides peptides -- are useful as well. Further, as those of skill in the art can readily appreciate, the present invention may be utilized to screen for peptide sequences that enhance transduction via endosomal escape or nuclear targeting when combined with ligand targeting agents. Accordingly, dual display peptides may be utilized for such screening, wherein one  
15 coat fusion or conjugate represents a known ligand and the other coat protein fusion or conjugate represents the sequence to be screened.

As with single display vectors, novel peptides or variants may be selected through rounds of cell contact and recovery of cells expressing the reporter gene, followed by identification of the encoded ligand.

20                   In yet other embodiments, combinations of elements that facilitate transduction may be utilized. For example a combination of UV and heat shock or heat shock and an endosomal escape peptide or nuclear targeting peptide may be utilized.

                  In yet another embodiment, cell attachment moieties (*e.g.*, peptides)  
25 may be chemically conjugated, non-covalent, (*e.g.*, electrostatic, antibody-antigen, biotin-streptavidin, etc.) or genetically fused to the exterior of the ligand display package. For example, many animal viruses encode sequences for both general cell binding and sequences specific for internalization. In this regard, adenovirus particles use both the knob protein (for receptor binding) and integrin binding for  
30 internalization. Highly charged proteins such as polylysine also facilitate binding to

the negatively charged cell membrane, but may also result in undesirable non-specific transduction of any cell. Thus, when non-specific transduction is sought, highly charged peptides such as polylysine, histone, etc. may be used. However, in the practice of the present invention preferred peptides are those that will bind to cells at low affinity and facilitate internalization only in the presence of a second displayed ligand (e.g., EGF). Examples include L-selectin, the sequences encoding known heparin binding peptides (e.g., residues 65-81 from FGF2 which have been implicated in heparin binding (Imamura *et al.*, *Biochem. Biophys. Acta* 1266:124-130, 1995)) and the heparin binding sequences identified in angio-associated migratory cell protein (Beckner *et al.*, *Cancer Res.* 55:2140-2149, 1995) that fit a heparin binding consensus RRXRRX (Cardin and Weintraub, *Arteriosclerosis* 9:21-32, 1995) and RGD containing sequences (Pierschbacher and Ruoslahti, *Nature* 309:30-33, 1984) that bind cell surface integrins.

As one of skill in the art can readily appreciate the selection methodologies described herein may be utilized to screen for additional cell attachment peptides. Briefly, cell attachment peptides may be conjugated or genetically fused to the exterior of a ligand display package. Typically, the cell attachment moiety will be attached to a display package such as a dual display phage such that an internalizing ligand and the cell attachment moiety will be jointly displayed. Accordingly, such joint display allows one of skill in the art to detect a change in transduction efficiency between packages displaying internalizing ligands alone and co-display in the presence of a cell attachment moiety (e.g., peptide).

In one example, to allow independent binding of the EGF-pIII fusion protein and the accessory cell attachment peptide, the cell attachment peptides are fused or conjugated to the phage major coat protein, pVIII (a small protein that makes up the tubular protein sheath that encapsulates the phage genome of which there are about 2700 copies per particle). Further, it has been established that pVIII can tolerate the addition of small peptides on its N-terminus (Ilyichev *et al.*, *FEBS Lett* 301:322-324, 1992; Makowski *Gene* 128:5-11, 1993) which is used to produce the so-called "landscape phage" (Petrenko *et al.*, *Protein Eng.* 9:797-801, 1999). Small

peptides (~ 6-8aa) may be fused directly to the N-terminus or made as substitutions in the middle of pVIII as described by Petrenko (*supra*). For larger peptides or where more than one peptide is to be inserted into or conjugated to the coat, a wild type pVIII protein may be included in the phage system as described for the dual display phagemid. Once sequences are found that enhance transduction efficiency in a representative cell line such as COS1 or other cells, the sequences may be further optimized by mutation and further selection by the ligand identification methods described herein.

As noted above, dual display vectors are useful within the context of the present invention. In dual display embodiments additional elements displayed on a coat protein (*e.g.*, pIII or pVIII) such as an endosomal escape sequence or random peptide sequence may be incorporated into or conjugated to the phage particle to enhance phage mediated transduction or to test for enhanced transduction. These elements enhance transduction by facilitating cell binding, endosomal escape, nuclear localization, and other points along the transduction pathway that are currently rate limiting. Accordingly, it would be advantageous to display separate elements on pIII and pVIII (or analogous exterior proteins) such that for example, the targeting ligand is expressed on pIII and the endosomal escape sequence on pVIII. Such separation may also minimize the possibility of interference of the function of one element with the other. Thus, a phagemid vector can be constructed that allows fusion and display of distinct peptides or proteins on both pIII and pVIII. For example, in one embodiment, only one pIII gene (the fusion) may be present when phage rescue is performed with pIII deleted helper phage. However, 2 pVIII genes are present: one on the phagemid (the pVIII fusion) and one (wild-type) on the helper phage. Thus the vector is designed to display a peptide or protein ligand on pIII and additional accessory peptide(s) or protein(s) on pVIII as a mosaic with wild type pVIII. Further, as there may exist an upper limit to displaying peptides on pVIII because peptides larger than about 8 residues interfere with assembly of the phage particle (Ilyichev *et al.* (*supra*); Makowski, (*supra*)), displaying the accessory protein as a mosaic allows

for proper particle assembly and the display of peptides larger than 6-8 residues on the major coat protein, pVIII.

Thus, an example of a dual display filamentous phage presents a ligand (e.g., FGF) as a fusion to gene III and an endosomal escape peptide fused to gene VIII. The locations of the ligand and escape sequences are interchangeable. Escape sequences that are suitable include, without limitation, the following exemplary sequences: a peptide of *Pseudomonas* exotoxin (Donnelly, J.J., *et al.*, *PNAS* 90:3530-3534, 1993); influenza peptides such as the HA peptide and peptides derived therefrom, such as peptide FPI3; Sendai Virus fusogenic peptide; the fusogenic sequence from HIV gp1 protein; Paradaxin fusogenic peptide; and Melittin fusogenic peptide (see WO 96/41606).

Another sequence that may be included in a vector is a sequence that facilitates trafficking proteins into the nucleus. These so-called nuclear translocation or nuclear localization sequences (NLS) are generally rich in positively charged amino acids. Because the carboxyl terminus of gene VIII protein of filamentous phage already carries a positive charge, increased charge and likelihood of nuclear transport may be enhanced by fusing known mammalian cell NLS sequences to the gene VIII protein. NLS fusions to other coat proteins of filamentous phage may be substituted.

Examples of NLS sequences include those resembling the short basic NLS of the SV40 T antigen; the bipartite NLS of nucleoplasmin; the ribonucleoprotein sequence A1; the small nuclear ribonucleoprotein sequence U1A, and human T-lymphocyte virus-1Tax protein. Other useful NLS sequences include the HIV matrix protein NLS; and the nuclear translocation components importin/hSRP1 and Ran/TC4; the consensus sequence KXX(K/R) flanked by Pro or Ala; the nuclear translocation sequence of nucleoplasmin; or the NLS from antennapedia (see WO 96/41606).

Further, sequences which direct the genetic package to various cellular compartments may be useful within the context of the present invention. For example, while FGF appears to be trafficked to the nucleus via a nuclear localization-

like peptide, EGF appears to be trafficked through the lysosome. Accordingly, in addition to the putative ligand, a lysosomal directing sequence may be incorporated into one of the coat proteins of the genetic package. Exemplary sequences in this regard are KCPL which acts as a lysosomal targeting sequence (Blagoveshchenskaya *et al.*, *J. Biol. Chem.* 273(43):27896-27903, 1998), the ubiquitin-dependent endocytosis motif DSWVEFIELD (Govers *et al.*, *EMBO J.* 18(1):28-36, 1999, and DQRDLI or EQLPML from MCHII which also target the lysosome (Kang *et al.*, *J. Biol. Chem.* 273(32):20644-20652, 1998).

As described herein, the library is then propagated in the display phage by transfection of a suitable bacteria host (*e.g.*, DH5 $\alpha$ F' for filamentous phages), and growing the culture, with the addition of a replication-competent helper virus (for phagemid vectors) if necessary, overnight at 37°C. The phage particles are isolated from the culture medium using standard protocols.

Infection of mammalian cells with phage is performed under conditions that block entry of wild type phage into cells (Barry *et al.*, *Nature Med.* 2:299-305, 1996). Phage are added directly to cells, typically at titers of  $\leq 10^{12}$  CFU/ml in a buffer, such as PBS with 0.1% BSA or other suitable blocking agents, and allowed to incubate with the cells at 37°C or on ice. The amount of phage added to cells will depend in part upon the complexity of the library. For example, a phage display library containing  $10^5$  members has each member represented  $10^6$  times in 1 ml of a typical phage titer of  $10^{11}$  colony forming units/ml.

## II. DETECTION/SELECTION OF TRANSGENE EXPRESSION

The genetic package display library is ultimately screened against the target tissue or cell line. Screening can be performed *in vitro* or *in vivo*. While combinatorial screening methods have been performed in the past, these methods are unable to determine the transduction capability of the displayed ligand (*see*, U.S. Patent No. 5,733,731, incorporated herein by reference). The criteria for a positive "hit" in the present invention is that the phage must be able to bind, be internalized, and enable detection of the internalized ligand by detecting a selectable marker, such

as, for example, by expressing the phage genomic DNA containing the reporter/selectable gene in the target or test cell or allowing direct nucleic acid detection (e.g., PCR or DNA binding). In this regard, while not wishing to be bound to a particular theory, it is believed that the phage should bind, internalize, uncoat, translocate to the nucleus, and replicate, in order to express the gene or otherwise facilitate detection (however, translocation and uncoating may occur in any order). Thus, in preferred embodiments only sequences that reach the nucleus are selected.

The test cells may be any cells that express a receptor of choice or may be a cell type or source for which gene therapy is destined. Thus, in some instances, the receptor may be unknown. In such cases, the selection method can be used to isolate a ligand for a receptor without a known ligand (orphan receptor) such as erbB3 or similar orphan receptor. Briefly, the orphan receptor is cloned into a mammalian expression vector that also contains a selectable drug resistance gene and transfected into mammalian cells, such as COS cells. Stable transfectants that overproduce the orphan receptor are selected by cultivation in the appropriate drug. This receptor-transformed COS cell line is then used as the cell line for selection of ligand-displaying phage.

In one aspect of the present invention, natural ligands (i.e., the naturally occurring ligand for a cell surface protein that internalize). In one embodiment a library of cDNAs that is representative of the sequences encoding all the protein domains made by a cell type or tissue are utilized. Briefly, the library is constructed using random oligonucleotide primers that have extensions encoding restriction enzyme recognition sites such that the final cDNA products can be cut with the restriction enzymes and ligated into an appropriate phage vector (e.g., MG4, pUC-MG4). For example, the first strand cDNA synthesis is primed with a random 6-mer oligonucleotide containing a PstI restriction site extension. The second strand synthesis is performed using a random 6-mer oligonucleotide extended with a NcoI restriction endonuclease. In this manner the cDNA fragments are cloned into the NcoI/PstI sites in a vector in the 5' to 3' direction. Thus only 3 possible reading frames out of 6 (if read off both coding and complementary strands) are inserted into

the vector and one or more of these orfs encodes a protein that is present in the cell. The resulting cDNA fragments may be size selected to obtain a population of a preferred size ranging from 30 to 1000 nucleotides. The preferred library is normalized to remove highly redundant sequences and increase the probability of  
5 selecting protein domains encoded by rare mRNAs. For example, normalization could be performed using subtractive hybridization to remove repetitive sequences (high Cot), (see e.g., Bonaldo *et al.*, *Genome Res.* 6:791-806, 1996). An alternative to random cDNA synthesis is to make a library of DNase fragmented cDNAs (from a library or from individual cDNAs) or using methods described by Roninson for the  
10 generation of GSEs (Gudkov *et al.*, *Proc. Natl. Acad. Sci. USA* 91:3744-3748, 1994) and others (Fehrsen and du Plessis, *Immunotechnology* 4:175-184, 1999; Petersen *et al.*, *Mol. Gen. Genet.* 249:425-431, 1995; Kay (*supra*)).

Following vector construction and phage production the phage cDNA library is contacted with cells or tissues that display the receptor for which the  
15 cognate ligand is sought and the ligand selected using the selection strategies described herein. The cell line may express the natural receptor or be engineered to overexpress a recombinant receptor gene that is stably expressed in that cell line using standard recombinant DNA methods. At 72 to 96 hours after phage addition the cells are harvested and the reporter gene (e.g. GFP) positive cells are collected.  
20 The sequences encoding the ligand are recovered by PCR or Hirt supernatant and the phage reconstituted and used as input phage for the next round or selection. The library is monitored at each round of selection by restriction enzyme analysis of phage DNA to determine if the complexity of the library has been sufficiently reduced to allow identification of one or more active ligands. The ligand encoding  
25 sequences are compared to databases of known genes to determine if the recovered sequence is a portion of a known gene. Alternatively, the ligand encoding cDNAs are used as probes of conventional cDNA libraries to identify the full-length gene using standard molecular biology protocols for identification of full-length cDNA from partial sequences.

The feasibility of the aforementioned approach can be evidenced by using the cDNA encoding the proopiomelanocortin (POMC) gene (which encodes six different peptide ligands) is fragmented at random by DNA 1, ligated to the appropriate linker adaptors (see Chapter 9 by Du Plessis and Jordaan in Kay *et al.*, 1998) and inserted into an appropriate phage or phagemid. The resulting library contains a mixture of DNA fragments, some of which will be inserted in-frame (1/3 if cloning is directional and 1/6 if cloning is bi-directional) with the pIII coat protein of the phage vector. The phages that display fragments encoding one of the six peptide ligands or a functional fragment thereof will bind and internalize in cells that display the appropriate receptor. The library is selected against cell lines that naturally express one of the receptors or against cells that are engineered to overexpress the receptor. For example, the POMC fragmented gene library is selected against COS cells that are made to overexpress the melanocortin1 receptor. Accordingly, the cDNA fragments that are selected encode the MSH- $\alpha$  peptide contained within the POMC cDNA. A series of overlapping cDNAs selected in this manner will define the minimal sequence that is sufficient to functionally interact with the melanocortin1 receptor. Thus, the minimal functional peptide is defined in a manner analogous to the identification of minimal epitopes for antibody binding using methods described by Geyson *et al.* (*J. Immunol. Meth.* 102:259-274, 1987). Similarly, the library may be selected against COS cells that overexpress ACTH or  $\beta$ -endorphin receptor to identify cDNAs encoding their cognate receptors.

In further embodiments, due to post-translational modifications the selection of natural ligands for mammalian cells may be enhanced by utilizing ligands produced in mammalian cells and conjugating such ligands to ligand display package of interest. Briefly, the cDNAs are expressed in mammalian cells thereby allowing post-translational processing and modification that takes place in these cells. In this regard, the phages may be conjugated to the mammalian cell synthesized library by non-covalent (*e.g.*, electrostatic, etc.) linkage (*e.g.*, an antibody-antigen epitope interaction, streptavidin-biotin, etc.) or by covalent means. The total cDNA is subcloned into a mammalian expression vector such as pSecTag2 (available from



Invitrogen, CA), that is designed to tag each cDNA gene product with a binding site for an antibody or other site specific protein-binding sequence (e.g., IgG binding domain). As many cDNA molecules may contain stop codons, an additional tag may be added downstream of the secretion signal, but upstream of the cDNA insert (e.g., HA etc.). The cells are transfected with an epitope tagged library and distributed into individual or pools of transfected cells. The conditioned media is removed from the cells, phage that display an epitope binding antibody fragment or other epitope binding moiety are added to the medium (at about  $10^{11}$  pfu/ml), and the mixture is added to fresh target cells. The phages bind the ligands via the displayed antibody and the epitope tag on the ligand. Those ligands that are internalized by the target cells direct phage-mediated transduction of the target cells. Positive transduction is detected by GFP fluorescence, drug selection, or any reasonable detection means. The cells that secrete functional ligands are identified as those from which transduction competent conditioned medium was drawn and the positive cDNAs are recovered by PCR. In the case of pools of cDNAs the pools are deconvoluted to identify individual cDNAs.

In yet additional embodiments, tissue-specific or tumor-specific ligands can be selected by pre-absorption of the phage library against normal or non-targeted tissues of cell cultures. The selection process can also be applied *in vivo* by injecting the library into tumor-bearing mice. The tumor is removed from the mouse 48-72h after injection. A cell suspension is prepared and phage genome bearing cells selected by one of the methods described herein. The gene whose product allows entry and expression of the phage genome is then isolated from the drug resistant cell colonies.

Screening may be performed directly against the target cells with no pre-screening or pre-enrichment. In one aspect, the present invention provides a method of identifying target cells or tissues for known or putative ligands. In this regard, phage display may be used to display a library of known or putative ligands (e.g., peptides, antibody fragments and the like) and screen singular tissues or cell types, or pools of tissues or cell types, thereby identifying target cells or tissues which

are effectively transduced by a ligand. As used herein, "pool" refers to two or more cell types or tissue types. In one embodiment, known ligands are presented on a ligand displaying genetic package to a pool of a variety of cell or tissue types and transgene expression is monitored. In a further embodiment, putative ligands are  
5 used to screen a pool of a variety of cell or tissue types for transduction ability. In this regard ligands may be recovered and identified which efficiently transduce a particular tissue or cell type. Identification of cell specific ligands could greatly improve existing vectors for therapeutic gene delivery by targeting specific cells thus reducing toxicity and allowing vectors to be administered systemically.

10           Such cell type or tissue-type screening provides for selection that requires biological interaction rather than simple binding and does not require recovery of infective phage. In addition, cell surface receptors need not be identified and purified for the screening to be effective. A further aspect of the present invention is that it can be easily adapted to high throughput applications for screening  
15 a variety of cell types or tissues and/or for screening libraries of putative ligands against libraries of putative receptors/binding partners (*i.e.*, anti-ligands) which lead to transgene expression (see *infra*). In this regard, screening of a variety of ligand/cell interactions could be performed, including, for example, pathogen/host interactions, ligand/receptor, etc.

20           In one aspect, the present invention may be utilized to identify a variety of protein-protein interactions. In particular, a set of unknown proteins/peptides may be selected based upon interaction with another set of known or unknown proteins/peptides (*e.g.*, random peptides, cDNA libraries, or antibody gene libraries). In one embodiment, putative ligands are displayed on the surface of  
25 filamentous phage that carry a reporter gene. These display phage are contacted with a cell line displaying a putative anti-ligand (protein/peptide) on its surface as a receptor fusion protein, such that binding of successful detection of the reporter gene requires binding of the phage display ligand and the cell surface displayed anti-ligand, as well as internalization and transgene expression. Such screening can be  
30 utilized in a variety of methods, for example, a known ligand may be screened against

a library of potential anti-ligands, a library of unknown ligands may be screened against a known protein/peptide anti-ligand, and two libraries of peptides/proteins may be screened against each other to identify ligand/anti-ligand interactions (protein-protein).

5           A ligand/anti-ligand pair refers to a complementary/anti-complementary set of molecules that demonstrate specific binding, generally of relatively high affinity. Exemplary ligand/anti-ligand pairs include an antibody and its ligand as well as ligand/receptor binding. While it should be understood that the designation of either component of the above mentioned ligand/anti-ligand pairs as  
10 either a ligand or anti-ligand is arbitrary, when necessary to specify a particular component, a "ligand", as used herein, is meant to describe peptides or proteins displayed on a genetic package carrying an expressible transgene. Further, when necessary to define anti-ligand with specificity, an "anti-ligand", as used herein, demonstrates high affinity and is expressed on the surface of the target cell to be  
15 monitored for transgene expression.

Any cell surface receptor may be used as the fusion construct for the cell surface displayed anti-ligand. However, in a preferred embodiment, the extracellular domain of the receptor is replaced with the putative anti-ligand. Construction of such fusions is routine in the art given that sequences as well as the  
20 extracellular intracellular domains of numerous receptors are known and available in the art. Komesli *et al.*, *Eur. J. Biochem* 254(3):505-513, 1998; Naranda *et al.*, *Proc. Natl. Acad. Sci. USA* 94(21):11692-11697, 1997; Rutledge *et al.*, *J. Biol. Chem.* 266(31):21125-21130, 1991; Lemmon *et al.*, *Embo J.* 16(2):281-294, 1997; Foehr *et al.*, *Immunol. Cell Biol* 76(5):406-413, 1998. Exemplary fusion constructs include,  
25 for example, anti-ligand-FGF receptor or anti-ligand-EGF receptor constructs.

In a further embodiment, a large pool of cDNAs may be tested by transfecting into a large number of mammalian cells (*e.g.*, COS cells). Ligand displaying phage are exposed to the transfected cells and positive cells identified by either drug selection or detection of an expressed transgene (*e.g.*, GFP sorted by  
30 FACs). PCR may be performed on single cells to identify ligand/anti-ligand binding

pairs. In this regard PCR primers directed to the known portion of the fusion construct may be used. For example, for phage display using pIII to display the ligand, the PCR primer will be directed to the pIII gene, while in order to identify the anti-ligand, the PCR primer will be directed to the surface membrane protein (*e.g.*, a  
5 receptor domain) encoding portion of the fusion construct. Alternatively, the plasmids within positive cells may be rescued by Hirt supernatant method and separated from phage DNA by gel electrophoresis or chromatography. (Kay *et al.*, *supra*). The selected cDNA plasmids may then be used to retransform bacteria. New plasmid DNA is prepared and used for additional rounds of screening by transfection  
10 into the cells and phage contact.

In an alternative embodiment, detection may be by any means which allows for the detection of the internalized nucleic acid molecules, and may include Hirt extraction of small DNA, direct polymerase chain reaction (PCR) amplification of ligand DNA from reporter gene expressing cells and non-endogenous protein-  
15 nucleic acid molecule binding interactions (*e.g.*, lac operon and lac repressor in a mammalian cell) in positive cells. In addition, it is possible to use direct PCR amplification of ligand DNA from cells wherein no reporter gene is used.

In the various embodiments of the present invention utilizing PCR amplification of ligand sequences, the methodologies allow for the rapid  
20 amplification of only internalized sequences. Typical phage display technologies require that the phage of interest (*e.g.*, that which binds to a particular target) be eluted and amplified following transduction of the appropriate host bacterial strain. However, transduction of bacteria requires that bacteriophage are intact and maintain infectivity. To eliminate the requirement for infective phage, methodologies  
25 provided herein allow those of ordinary skill in the art to recover, by PCR, phage DNA sequences that have been trafficked to the nucleus, digest these sequences with appropriate restriction enzymes, remove extraneous sequences, subclone the desired sequences back into the phage display vector, and transform bacteria with this vector. Accordingly, by not requiring that the recovered phage be infective, the ability to  
30 display larger ligands as fusion constructs with coat proteins is possible. Further,

recovery of uncoated phage, such as those targeted to the lysosomal or endosomal compartments, as well as those capable of directing expression in the nucleus is possible.

Briefly, in one aspect, the recovery by PCR and amplification proceeds as follows: An initial selection of cells is performed using the detection of a reporter gene, selective conditions, or the like and the total DNA is recovered from these cells. The recovered DNA is used as a template for PCR primers that are designed to flank the sequence of interest (the ligand encoding sequence, *i.e.*, by using the pIII or pVIII sequences flanking the ligand insert as primer templates). The primers can be manufactured such that they can be easily removed from the ligand insert following restriction enzyme digestion, for example, the primers may contain a biotin moiety at the 5'-end. In the alternative, the primers may be removed by any known methods, including, for example, gel extraction, selective precipitation, and the like. In other alternatives primers need not be removed, however their removal facilitates ligation efficiency of ligand insert to vector. Further, the primers can provide restriction sites for subcloning etc.

Following amplification, the PCR product is purified to remove the polymerase and digested with restriction enzyme to excise the putative ligand insert. Enzymes are chosen in order to facilitate directional subcloning into either the original vector or a new construct, if so desired. Following enzyme digestion, the extraneous sequences are removed (*e.g.*, by using biotinylated primers and streptavidin conjugated to beads or other solid support). The resulting DNA sequences are then ligated into the desired vector and the resulting vector is transformed into bacteria using standard methodologies. The transformed bacteria are then used to generate new phage particles or new DNA for additional rounds of screening. However, while it should be understood that the use of a reporter gene may lead to enhanced DNA recovery and fewer rounds of screening, there is not always a requirement that a reporter gene be used.

In an alternative embodiment, recovery of replicated internalized nucleic acid molecules may be achieved via a nucleic acid binding domain.

Accordingly, when using phage, the phage genome can be altered such that a DNA binding sequence is incorporated therein. In one example, the phage vector may contain one or more copies of the lac operon, thereby allowing any internalized and replicated phage vectors to be purified from a cell lysate by a solid surface having conjugated thereto the lac repressor protein. Briefly, target cells are contacted with  
5 ligand displaying genetic packages (*e.g.*, phage) for 48 to 72 hours. Since only the packages displaying an appropriate ligand are internalized and reach the cell nucleus where vector replication takes place, these will be the sequences that will be selected for and thus, no reporter gene is required (*e.g.*, GFP). Accordingly, the replicated  
10 vector is double stranded and the double stranded form of the lac operon will bind the lac repressor. The cells are then lysed and nuclear extracts are prepared, which are then passed over a solid support (*e.g.*, Sepharose 4B) having conjugated thereto the lac repressor protein. The column is washed, then eluted by a salt or pH gradient, thereby releasing the bound DNA which can now be utilized in PCR reactions to  
15 amplify the ligand sequences for sub-cloning into another vector for further rounds of infection or characterization or the DNA can be used directly (without PCR) to transform bacteria and thereby produce more phage for further screening.

In other embodiments, the ligand displaying genetic package may also contain the nucleic acid sequences that encode the nucleic acid binding protein. For  
20 example, in the illustration above, the vector could also encode the lac repressor and the solid support has an anti-lac repressor antibody conjugated thereto, thereby allowing for recovery of nucleic acid molecules bound by the lac repressor.

One of ordinary skill in the art would readily recognize that a variety of nucleic acid binding proteins could be utilized as described above. In this regard,  
25 many proteins have been identified that bind specific sequences of DNA. These proteins are responsible for genome replication, transcription and repair of damaged DNA. The transcription factors regulate gene expression and are a diverse group of proteins. These factors are especially well suited for purposes of the subject invention because of their sequence-specific recognition. Host transcription factors  
30 have been grouped into seven well-established classes based upon the structural motif

used for recognition. The major families include helix-turn-helix (HTH) proteins, homeodomains, zinc finger proteins, steroid receptors, leucine zipper proteins, the helix-loop-helix (HLH) proteins, and  $\beta$ -sheets. Other classes or subclasses may eventually be delineated as more factors are discovered and defined. Proteins from those classes or proteins that do not fit within one of these classes but bind nucleic acid in a sequence-specific manner, such as SV40 T antigen and p53 may also be used.

These families of transcription factors are generally well-known (see GenBank; Pabo and Sauer, *Ann. Rev. Biochem.* 61:1053-1095, 1992; and references below). Many of these factors are cloned and the precise DNA-binding region delineated in certain instances. When the sequence of the DNA-binding domain is known, a gene encoding it may be synthesized if the region is short. Alternatively, the genes may be cloned from the host genomic libraries or from cDNA libraries using oligonucleotides as probes or from genomic DNA or cDNA by polymerase chain reaction methods. Such methods may be found in Sambrook *et al.*, *supra*.

Helix-turn-helix proteins include the well studied  $\lambda$  Cro protein,  $\lambda$ cI, and E. coli CAP proteins (see Steitz *et al.*, *Proc. Natl. Acad. Sci. USA* 79:3097-3100, 1982; Ohlendorf *et al.*, *J. Mol. Biol.* 169:757-769, 1983). In addition, the lac repressor (Kaptein *et al.*, *J. Mol. Biol.* 182:179-182, 1985) and Trp repressor (Scheritz *et al.*, *Nature* 317:782-786, 1985) belong to this family. Members of the homeodomain family include the Drosophila protein Antennapedia (Qian *et al.*, *Cell* 59:573-580, 1989) and yeast MAT $\alpha$ 2 (Wolberger *et al.*, *Cell* 67:517-528, 1991). Zinc finger proteins include TFIIIA (Miller *et al.*, *EMBO J.* 4:1609-1614, 1985), Sp-1, zif268, and many others (see generally Krizek *et al.*, *J. Am. Chem. Soc.* 113:4518-4523, 1991). Steroid receptor proteins include receptors for steroid hormones, retinoids, vitamin D, thyroid hormones, as well as other compounds. Specific examples include retinoic acid, knirps, progesterone, androgen, glucocorticoid and estrogen receptor proteins. The leucine zipper family was defined by a heptad repeat of leucines over a region of 30 to 40 residues. Specific members of this family include C/EBP, c-fos, c-jun, GCN4, sis-A, and CREB (see generally

O'Shea *et al.*, *Science* 254:539-544, 1991). The helix-loop-helix (HLH) family of proteins appears to have some similarities to the leucine zipper family. Well-known members of this family include myoD (Weintraub *et al.*, *Science* 251:761-766, 1991); c-myc; and AP-2 (Williams and Tijan, *Science* 251:1067-1071, 1991). The  $\beta$ -sheet  
5 family uses an antiparallel  $\beta$ -sheet for DNA binding, rather than the more common  $\alpha$ -helix. The family contains the MetJ (Phillips, *Curr. Opin. Struc. Biol.* 1:89-98, 1991), Arc (Breg *et al.*, *Nature* 346:586-589, 1990) and Mnt repressors. In addition, other motifs are used for DNA binding, such as the cysteine-rich motif in yeast GAL4 repressor, and the GATA factor. Viruses also contain gene products that bind  
10 specific sequences. One of the most-studied such viral genes is the rev gene from HIV. The rev gene product binds a sequence called RRE (rev responsive element) found in the env gene. Other proteins or peptides that bind DNA may be discovered on the basis of sequence similarity to the known classes or functionally by selection. Furthermore, those of ordinary skill in the art will appreciate that the nucleic acid  
15 binding domain will chosen for a particular recovery method will preferably be one which is not already present within the target cells.

In a further embodiment, known or putative ligand-display phage may be used to screen a panel of cells that each express a potential target receptor. The source of the target receptor may be a known (*i.e.* cloned) receptor cDNA, or a  
20 collection of putative receptor cDNAs. For example, the putative receptor cDNAs may be identified from an epitope-tagged cDNA library as cDNAs that encode proteins that appear on the surface of cells. (see, Sloan *et al.*, *Protein Expression and Purification* 11:119-124, 1997). Such cDNAs are inserted into an appropriate mammalian expression vector and transfected into a host cell. Preferably the host cell  
25 is eukaryotic, and more preferably the host cell is mammalian. The expression of the cDNA may be either stable or transient. Following expression the cells are contacted with the ligand-display phage and monitored for transgene expression (*e.g.*, drug resistance, GFP, or other detectable product). One skilled in the art would recognize that identification of cell or tissue types as described above, in addition to using  
30 ligand display phage, could also performed by utilizing other ligand displaying



means, such as RNA-peptide fusions as described by Roberts and Szostak (*Proc. Nat. Acad. Sci. USA* 94:12297-12302, 1997), other phage types, viruses, or on bacteria.

Pre-screening or pre-enrichment may be used and can be especially helpful when either too few or too many hits are observed. Enrichment for cell binding may improve detectability if no hits are found in the initial screen. A prescreen to remove phage that bind non-specific cells surface proteins may reduce non-specific hits if there are too many initial hits. For example, infection of  $10^7$  target cells is performed with about  $10^{11}$  phage, however a variety of cell density and phage titer ranges are useful. The cells are incubated for at least 2 hours and preferably 24-48 hours in PBS/BSA and washed extensively (Barry *et al.*, *Nature Med.* 2:299-305, 1996). The cells are incubated in media at 37°C for 24-96 hours and then detected or selected on the basis of expression of the reporter gene.

Assays for each of these reporter gene products are well known. For example, GFP is detected by fluorescence microscopy or flow cytometry, SEAP is detected in medium using a fluorescent substrate (Clontech; Palo Alto, CA), human growth hormone may be detected in medium by a simple and sensitive radioimmune assay (Nichols Institute; CA). Western blotting and ELISA may also be used to immunologically detect and measure the presence of reporter gene product. Alternatively, the message for the reporter gene is detected using RNase probe protection or fluorescent probe hybridization. For isolation of the phage vector DNA and insert, any technique that can identify and isolate the cells expressing detectable marker product may be used. Flow cytometry, in particular, is well suited for detecting fluorescence in or on a cell and isolating that cell. Further, flow cytometry is well suited for high throughput methodologies when necessary to isolate individual cells or groups of cells that express a reporter gene.

When the reporter gene is a selectable marker, the cells are grown in selective conditions. Depending upon the marker, the conditions may be a particular growth temperature, addition of a drug, or the like. In the examples provided herein, the selectable marker is neomycin transferase, which confers G418 resistance on mammalian cells. Briefly, the cells are grown in the presence of G418 for 7-14 days

or until resistant colonies are visible microscopically. Colonies are picked, and phage vector DNA recovered, conveniently as amplification of the insert or Hirt supernatant.

Alternatively, multiple rounds of infection and selection are performed  
5 to reduce the complexity of the infecting phages. For example, drug-resistant colonies are pooled and the selected inserts amplified and cloned back into the phage display vector for a new round of infection. When the reporter is fluorescent, flow cytometry can be used to select the strongest fluorescing cells to select the most highly efficient gene delivery ligands. More stringent screening conditions also  
10 include higher selective drug concentrations. At the completion of a selection process, representative phage clones may be subjected to DNA sequence analysis to further characterize gene delivery ligands.

In a further aspect, high throughput screening methodologies, such as screening libraries by sub-selection of pools, may be utilized to identify ligands.  
15 Briefly, phage stocks containing a variety of members, as individual plaques, may be used in combination with an array to identify potential internalizing ligands. For example, a stock of bacteriophages containing library members may be divided into subset pool stocks such that each stock contains about  $10^2$  to about  $10^3$  members. Each stock solution is then screened utilizing an array (*e.g.*, multi-well plates  
20 containing target cells). Upon detection of a reporter gene the phage stock may be sub-divided again and screened repeatedly until the phage which contains the internalizing ligand is identified. Alternatively, those of skill in the art will appreciate that the array may contain a variety of cell types which are capable of being screened with one or more phage libraries, of which may also include a variety of reporter  
25 genes (if so desired). For example, a variety of alternatively colored fluorescent protein expression vectors are available which can be used as reporter genes to provide multiplexing capability (Clontech, Palo Alto, CA). Accordingly, rapid identification of those cells which internalize the bacteriophage and/or libraries that contain internalizing ligands for a specific cell type, may be identified. Utilizing both  
30 a variety of bacteriophage libraries as well as a variety of cell types, would allow for a

high throughput method of determining subsets of libraries that contain ligands for specific cell types, simultaneously. Array's for binding biomolecules are known in the art and therefore could be adapted to utilize the phage screening methodology of the present invention, *see, e.g.*, PCT Application No. WO 95/11755, PCT Application  
5 No. WO 95/35505, U.S. Patent No. 4,591,570. In addition, affinity based biosensors such as a Biacore instrument, available commercially from Biacore AB, Uppsula, Sweden, may be used to immobilize phage or cells for high throughput screening.

Moreover, while commonly used high throughput methodologies which utilize live cells are typically performed on arrays of 6 to 96 well plates, the  
10 current invention may also be carried out using cellular micro-arrays such as those described by U.S. Patent No. 5,776,748. Briefly, such arrays may be manufactured such that designated areas of the array bind a defined number of cells or size of tissue. For example, the arrays can be constructed such that they bind only a single cell. Therefore, an array of single cells may be constructed with a variety of cell or tissue  
15 types. Because the size of the cell binding islands on the array may be chosen such that no more than one cell may bind on any given island, because the locations and geometric pattern of the islands may be predetermined, and because the cells will remain at fixed locations during assaying, cellular micro-arrays can provide for a high efficiency and high throughput method of assaying for internalizing ligands, anti-  
20 ligands, or target cells or tissues.

In a preferred embodiment flow cytometry is utilized, the cells are identified and counted by an automated detector unit. Because the locations and geometric patterns of the islands are predetermined, the detector can be designed or programmed to take measurements specifically at those locations. Therefore,  
25 identification of individual cells which have been successfully transduced by a ligand displaying genetic package carrying a nucleic acid molecule which encodes a detectable product is easily accomplished. In some embodiments, cells transduced by a ligand displaying genetic package carrying a nucleic acid molecule which encodes a selectable marker may be first selected on the basis of the appropriate sensitivity or  
30 resistance and then plated as individual cells and further selected or characterized by

the methods described herein. In particular, selection may be employed prior to plating on the plates to isolate transformed or transfected cells and then the cells may be assayed *in situ*.

In addition, when using fluorescence assays, a detector unit may be placed above the plate or, if the plate is translucent, below the plate. In the case of transmission spectrophotometric assays, a translucent plate is used, a source of electromagnetic radiation is placed on one side of the plate and a detector unit on the other. Because of the small distances between individual isolated cells permitted by the present invention, detectors employing fiber optics are particularly preferred.

Such sources of electromagnetic radiation and such detectors for electromagnetic transmission, reflection or emission are known in the applicable art and are readily adaptable for use with the invention disclosed herein.

Screening *in vivo* may be performed similar to methods for targeting organs or xenograft tumors using phage displayed peptides (Pasqualini *et al.*, *Nature Biotech.* 15: 542-546, 1997; Pasqualini *et al.*, *Nature* 380: 364-366, 1996), except that the tissues, organs, or tumors are examined for reporter gene expression instead of the presence of phage. Briefly, a phage display library is injected intravenously into animals, generally mice, and organs or tumor samples are tested for reporter gene function at 48-96 hours after injection. Tumor cells may be cultured in selective conditions or sorted by flow cytometry or other method to enrich for cells that express the phage transducing gene. The ligand encoding sequences can be amplified from selected cells as described above. As in *in vitro* screening, repeated rounds of infection and re-screening, alone or in combination with increased screening stringency, may be used to obtain the most efficient gene delivery ligands.

Specificity may also be examined *in vitro* using a panel of non-targeted and targeted cell lines and detecting expression of the phage transducing gene. Competition studies with free ligand or a neutralizing antibody to the ligand or receptor are used to confirm specific entry of phage via the ligand receptor complex. Alternatively, the cloned receptor for the ligand can be overexpressed in a cell line that normally does not express that receptor. Phage internalization and expression

into the stable transfectants expressing the receptor but not the parent cell line indicates the specificity of the ligand for its receptor on receptor bearing cells.

Ligands that are identified as gene targeting ligands using the selection strategies described herein may be further tested for specificity by reporter gene  
5 expression in target and non-target cells and tissues. The ligand may also be tested in a variety of gene delivery methods, such as ligand-polylysine/DNA complexes (Sosnowski *et al.*, *J. Biol. Chem.* 272:33647-33653, 1996) or retargeted adenovirus gene delivery (Goldman *et al.*, *Cancer Research* 57:1447-1451, 1997).

The specificity of the targeting ligand may alternatively be determined  
10 *in vivo* by biodistribution analysis using one of the reporter genes described herein, such as luciferase. At various time points, mice injected with the ligand displaying phage are sacrificed and tissues examined for the presence of phage in non-targeted tissues by immunohistochemistry, an enzymatic assay that detects reporter product activity, or the like.

15

### III. USES

The methods described herein are designed to select cDNAs, Fabs, sFv, random peptides, and the like for discovery of new ligands or anti-ligands. They can also be used to select mutated and gene-shuffled versions of known ligands for  
20 targeting ability.

These ligands may have increased transduction efficiency (as measured by an increase in the percentage of infected cells that express the reporter gene); increased expression of the reporter gene (as measured by intensity of reporter gene expression) in the phage transduced cells; increased specificity of transduction  
25 for target cells (as measured for ligand specificity); increased stability of the ligand (as measured by ability to target the ligand *in vivo* to tumor cells); increased affinity for receptor (*e.g.*, removing dimerization requirements for ligands that dimerize); increased functionality (*e.g.*, stimulates internalization); elimination of the need for cofactors (*e.g.*, development of an FGF variant that binds with high affinity to the

FGF receptor but not to heparin); altered specificity for receptor subtypes (*e.g.*, an FGF variant that reacts with only one of the four FGF receptors).

The ligands identified by the methods described herein may be used as targeting agents for delivering therapeutic agents to cells or tissues. For example, a therapeutic gene can be incorporated into the phage genome and delivered to cells via phage bearing the gene delivery ligand on its protein coat.

A transducing gene, as used herein, refers to a gene which encodes a detectable product in the target cell. Preferentially, the transducing gene is a therapeutic gene. A "therapeutic nucleic acid" or "therapeutic gene" describes any nucleic acid molecule used in the context of the invention that effects a treatment, generally by modifying gene transcription, translation, or which supplies a replacement or amplification of an existing gene. It includes, but is not limited to, the following types of nucleic acids: nucleic acids encoding a protein, ribozyme, antisense nucleic acid, DNA intended to form triplex molecules, protein binding nucleic acids, and small nucleotide molecules. As such, the product of the therapeutic gene may be DNA or RNA. These gene sequences may be naturally-derived sequences or recombinantly derived. A therapeutic nucleic acid may be used to effect genetic therapy by serving as a replacement for a defective gene, by encoding a therapeutic product, such as TNF, or by encoding a cytotoxic molecule, especially an enzyme, such as saporin. The therapeutic nucleic acid may encode all or a portion of a gene, and may function by recombining with DNA already present in a cell, thereby replacing a defective portion of a gene. It may also encode a portion of a protein and exert its effect by virtue of co-suppression of a gene product.

As discussed above, the therapeutic gene is provided in operative linkage with a selected promoter, and optionally in operative linkage with other elements that participate in transcription, translation, localization, stability and the like.

The therapeutic nucleotide composition of the present invention is from about 20 base pairs to about 100,000 base pairs in length. Preferably the nucleic acid molecule is from about 50 base pairs to about 50,000 base pairs in length. More

preferably the nucleic acid molecule is from about 50 base pairs to about 10,000 base pairs in length. Even more preferably, it is a nucleic acid molecule from about 50 pairs to about 4,000 base pairs in length.

The ligands/anti-ligands provided herein are useful in the treatment  
5 and prevention of various diseases, syndromes, and hyperproliferative disorders, such as restenosis, other smooth muscle cell diseases, tumors, such as melanomas, ovarian cancers, neuroblastomas, pterygii, secondary lens clouding, and the like. As used herein, "treatment" means any manner in which the symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also  
10 encompasses any pharmaceutical use of the compositions herein. As used herein, "amelioration" of the symptoms of a particular disorder refers to any lessening, whether permanent or temporary, lasting or transient, that can be attributed to or associated with administration of the composition.

In certain embodiments, the compositions of the present invention may  
15 be used to treat angiogenesis-dependent diseases. In these diseases, vascular growth is excessive or allows unwanted growth of other tissues by providing blood supply. These diseases include angiofibroma, arteriovenous malformations, arthritis, atherosclerotic plaques, corneal graft neovascularization, delayed wound healing, diabetic retinopathy, granulations due to burns, hemangiomas, hemophilic joints,  
20 hypertrophic scars, neovascular glaucoma, nonunion fractures, Osler-weber syndrome, psoriasis, pyogenic granuloma, retrolental fibroplasia, scleroderma, solid tumors, trachoma, and vascular adhesions.

By inhibiting vessel formation (angiogenesis), unwanted growth may be slowed or halted, thus ameliorating the disease. In a normal vessel, a single layer  
25 of endothelial cells lines the lumen, and growth of the vessel requires proliferation of endothelial cells and smooth muscle cells.

As well, the ligands, anti-ligands, and cells identified by the present invention may be used to treat tumors. In these diseases, cell growth is excessive or uncontrolled. Tumors suitable for treatment within the context of this invention  
30 include, but are not limited to, breast tumors, gliomas, melanomas, prostate cancer,

hepatomas, sarcomas, lymphomas, leukemias, ovarian tumors, thymomas, nephromas, pancreatic cancer, colon cancer, head and neck cancer, stomach cancer, lung cancer, mesotheliomas, myeloma, neuroblastoma, retinoblastoma, cervical cancer, uterine cancer, and squamous cell carcinoma of skin. For such treatments, 5 ligands are chosen to bind to cell surface receptors that are generally preferentially expressed in tumors.

Through delivery of the compositions of the present invention, unwanted growth of cells may be slowed or halted, thus ameliorating the disease. The methods utilized herein specifically target and kill or halt proliferation of tumor 10 cells having receptors for the ligand on their surfaces.

The identified ligands/anti-ligands may also be used to treat or prevent atherosclerosis and stenosis, a process and the resulting condition that occurs following angioplasty in which the arteries become reclogged. Generally, treatment of atherosclerosis involves widening a stenotic vascular lumen, permitting greater 15 blood flow and oxygenation to the distal tissue. Unfortunately, these procedures induce a normal wound healing response in the vasculature that results in restenosis. Of the three components to the normal vascular response to injury, thrombosis, elastic recoil and smooth muscle cell proliferation, anti-thrombotics/platelet inhibitors and vascular stents effectively address acute/subacute thrombosis and elastic recoil, 20 respectively. However, no existing therapy can modify the vascular remodeling that is due to proliferation of smooth muscle cells at the lesion, their deposition of extracellular matrix and the subsequent formation of a neointima. Accordingly, phage could be used to deliver therapeutic nucleic acids or proteins that would inhibit restenosis.

25 Wound response also occurs after other interventions, such as balloon angioplasty of coronary and peripheral vessels, with or without stenting; carotid endarterectomies; vein grafts; and synthetic grafts in peripheral arteries and arteriovenous shunts. Although the time course of the wound response is not well defined, if the response can be suppressed for a short term (approximately 2 weeks), a 30 long term benefit is achieved.



In other various embodiments the applications of the technology described herein is virtually limitless. For example, bacteriophage may be retargeted (*e.g.*, redirected from their native binding) using ligands added to their coat to treat bacterial disease in plants and animals. Briefly, ligands may be screened against a  
5 variety of pathogenic bacteria and ligands which effectively deliver expressible products to the interior of the cell may be utilized to shuttle toxic components selectively into these bacteria. One of ordinary skill in the art would readily recognize that the methods described herein may be modified to alter the native binding of a bacteriophage such that the bacteriophage binds and injects its contents  
10 or is internalized thereby delivering its contents in select bacteria. Accordingly, once ligands are identified the bacteriophage may be used to delivery cytotoxic expression plasmids to the interior of the bacteria or alternatively the ligands may be attached to toxic chemical moieties that will be delivered to the bacteria in high concentrations via the ligand targeting agent. Further, the mere delivery of a replication competent  
15 phage to a bacteria could induce death by cell lysis, thereby creating a bacteriophage antibiotic, specifically targeted to select bacteria. Such targeting may also be extended to targeting plant cells, yeast, fungi, and virtually any other cell or microorganism. For example, food production may be enhanced by transducing yeast or cheese producing bacteria with bacteriophage carrying a gene of interest and  
20 targeted to the yeast or bacteria using a ligand identified by the methods described herein.

The present invention provides the capability of identifying ligands which internalize as well as proteins, antibodies, cell/cell interacting proteins that define the interrelationships between cells, host/pathogen, tumor/stroma,  
25 autocrine/paracrine factors and allows identification of molecules that are targets for new drug discovery or are themselves therapeutically or diagnostically useful. Further, other peptides can be discovered by the methodologies taught herein that enhance endosomal escape, nuclear localization, cell binding, and thus discover ligands that are useful not only in phage mediated gene therapy, but generally

applicable to standard gene therapy methodologies (*e.g.*, enhancing gene expression from animal viral vectors, DNA-conjugates etc.)

The following examples are offered by way of illustration, and not by way of limitation.

## EXAMPLES

EXAMPLE 1

## MODIFIED PHAGE VECTORS FOR MAMMALIAN CELL TRANSDUCTION

5 A mammalian expression cassette is inserted into a phage or phagemid vector and is used to detect ligand mediated phage entry via reporter gene expression in mammalian cells. A type 3 filamentous phage vector is modified for transduction of mammalian cells by insertion of a GFP expression cassette consisting of a CMV  
10 mammalian transcriptional promoter, the green fluorescent protein gene from pEGFP-N1 (Clontech; Palo Alto, CA), and a bovine growth hormone transcriptional terminator and polyadenylation signal to make the vector, MEGFP3 (see Figure 1A). The mammalian expression cassette also contains an SV40 origin of replication adjacent to the CMV promoter. Similar constructs for monitoring entry and  
15 subsequent expression of phage genomes in mammalian cells are constructed from other known phage or phagemid vectors including pCANTAB 5 E (Pharmacia Biotech; Piscataway, NJ) or M13 type 3 or 33 for gene III fusions (see Kay *et al.*, *Phage Display of Peptides and Proteins: A Laboratory Manual*, Academic Press, 1996; McConnell *et al.*, *Mol. Divers. 1*:165-176,1996) and M13 type 8 or 88 vector  
20 for fusions to gene VIII protein (Roberts *et al.*, *Methods Enzymol.* 267:68-82, 1996; Markland *et al.*, *Gene* 109:13-19, 1991).

EXAMPLE 2

## CONSTRUCTION OF FGF2-CONTAINING PHAGE DISPLAY VECTORS

25 In the following examples, a phage that displays FGF2 on its surface is used to bind to the FGF2 receptor on mammalian cells and be internalized. An FGF2 gene is subcloned into the modified M13 phage type 3 vector, MEGFP3, to create the ligand display phage, MF2/1G3 (see Figure 1B). The gene may also be mutated such  
30 that it encodes an FGF2 (C96S) (C78S) double mutant which enhances expression

efficiency. The MEGFP3 vector has been modified with a mammalian expression cassette designed to express the reporter gene GFP to monitor mammalian cell transduction by the phage. Other vectors include pCANTAB 5 E (Pharmacia Biotech; Piscataway, NJ) or M13 type 3 or 33 for gene III fusions (see Kay *et al.*,  
5 *Phage Display of Peptides and Proteins: A Laboratory Manual*, Academic Press, 1996; McConnell *et al.*, *Mol. Divers.* 1:165-176,1996). Similarly, FGF2 is cloned into M13 type 8 or 88 vector for fusion to gene VIII protein (Roberts *et al.*, *Methods Enzymol.* 267:68-82, 1996; Markland *et al.*, *Gene* 109:13-19, 1991).

To facilitate cloning, the FGF2 gene is amplified by PCR using  
10 oligonucleotide primers that contain appropriate restriction endonuclease sites in the phage vector gene III or VIII genes. The resulting phage express FGF2 on their surface coat as detected by anti-FGF2 antibodies in Western blots (Figure 2) and by ELISA (Figure 3).

Western blot detection of FGF2-pIII fusion utilizes extracts from  
15 equivalent phage titers of purified FGF2 phage and control phage (MEGFP3) separated by polyacrylamide gel electrophoresis and blotted onto nitrocellulose. FGF2 and FGF2-fusion phage are detected with an anti-FGF2 monoclonal antibody (Transduction Labs; Lexington, KY) and HRP conjugated anti-mouse secondary antibody (American Qualex; San Clemente, CA) with chemiluminescent  
20 development. A single protein band is detected in the cesium chloride purified FGF2-phage extract migrating at about 80 kDa. This is about the size predicted for the FGF2-pIII fusion protein (FGF2 (18kDa) fused to pIII (migrates ~60kDa)). CsCl purification is performed to remove any non-covalently bound FGF2 fusion protein from the phage particles.

25 Binding of the FGF2 fusion phage to FGF2 receptor is assessed by ELISA in which recombinant FGF2 receptor is attached to the solid phase and an anti-phage antibody is used as the primary detection antibody. Briefly, phage were captured with an anti-FGF2 rabbit polyclonal antiserum bound to the plate well. An HRP conjugated anti-M13 antibody (Pharmacia Biotech; Piscataway, NJ) was used to  
30 detect the bound phage. When anti-phage antibody is used to capture the phage and

equivalent OD is observed for both control (MEGFP3) and FGF2-phage (MF2/1G3) indicating that equivalent phage particles are applied to the plate (Figure 3A). In Figure 3B an increased OD indicates the presence of FGF2 on the MF2/1G3 FGF2-phage.

5

### EXAMPLE 3

#### TARGET CELL LINE ENGINEERING

To increase the sensitivity of the assay for transduction by ligand display phage the target cell line is transfected with a plasmid that is designed to express the SV40 large T-antigen (*i.e.* pSV3neo). This plasmid also contains a drug selection gene such as neomycin phosphotransferase (neo) which confers resistance to the antibiotic G418 in stably transfected mammalian cells. Following transfection of the target cell line with plasmid DNA using standard methods (*i.e.* CaPO<sub>4</sub> co-precipitation) the cells are split and maintained in G418 containing media until drug resistant colonies appear. The colonies are expanded to test for SV40 T-antigen synthesis by western blotting or immunoprecipitation using a suitable antibody. Examples of T-antigen expressing target cell lines are: BOS (BHK with SV40 T-Ag) for screening FGF variants; HOS-116 (HCT116 with SV40 T-Ag) for screening peptides that target human colon carcinoma; AOS-431 (A431 with SV40 T-Ag) for screening EGF variants (all parent cell lines are available from ATCC, Manassas, VA)

25

### EXAMPLE 4

#### BINDING AND INTERNALIZATION OF FGF2-EXPRESSING PHAGE

The FGF2-expressing phage are also assayed for high affinity receptor binding and internalization in receptor bearing cells by immunolocalization and fluorescence microscopy (Hart, *J. Biol. Chem.* 269:12468-12474, 1994; Barry *et al.*, *Nature Med.* 2:299-305, 1996; Li, *Nature Biotech.* 15:559-563, 1997).

30

Infection of mammalian cells with FGF2-expressing phage is performed under conditions that block entry of wild type M13 phage into cells except chloriquine is not used (Barry *et al.*, *supra*). Phage are added directly to cells at titers of  $\leq 10^{10}$  CFU/ml in PBS with 0.1% BSA or other suitable blocking agents and  
5 incubated at 37°C or on ice for at least 1 hour. The cells are then washed extensively in PBS, fixed in 2% paraformaldehyde, and permeabilized in 100% methanol at room temperature for 10 minutes. Cells are incubated with rabbit anti-M13 antibody (Sigma; St. Louis, MO) in PBS/BSA for 1 hour. The primary antibody is detected with a phycoerythrin labeled anti-rabbit antibody (Life Technologies (Gibco BRL);  
10 Rockville, MD). Surface bound (incubated on ice) or internalized (37°C incubation) phage are detected by fluorescence microscopy.

#### EXAMPLE 5

##### TRANSDUCTION OF MAMMALIAN CELLS BY FGF2-LIGAND DISPLAY PHAGE

15

FGF2 display phage (MF2/1G3) and an identical phage that lacks the FGF2 gene (MEGFP3) are compared for receptor mediated internalization and reporter gene expression in COS cells. The phage are incubated with the cells for 4 hours at 37°C in DME (Dulbecco's modified Eagles medium, Life Technologies  
20 (Gibco BRL); Rockville, MD) containing 2% BSA (bovine serum albumin) as a blocking agent. After washing to remove unbound phage the cells are returned to the incubator for an additional 72 hours. Transduction is measured by counting GFP positive autofluorescent cells. As shown in Figure 4B, the FGF2 display phage result in about a 10 fold greater transduction efficiency than the control phage indicating  
25 that the displayed FGF2 ligand on the surface of the phage particles results in receptor mediated binding and internalization of phage with subsequent expression of the phage reporter gene. The specificity of the FGF2-phage mediated transduction is demonstrated by successful inhibition of transduction with excess free FGF2 (2µg/ml) (Figure 4B). The low level nonspecific uptake and transduction by the  
30 control phage (MEGFP3) is not affected by the presence of excess FGF2.

It is important to show that the MEGFP3 control phage is equally capable of transducing mammalian cells as the display phage when appropriately targeted. To compare the transduction ability of both the FGF2-phage and the control phage, equivalent titers of each phage were used to transfect COS cells using a 5 avidin-biotin FGF2 targeting method. In this method biotinylated FGF2 is contacted with the cells and used to capture phage particles via the addition of avidin and a biotinylated anti-phage antibody. The phage/FGF2/cell binding is performed on ice, unbound phage removed by washing, cells returned to the incubator at 37°C, and transduction assessed at 72 hours. As seen in Figure 4A, there is no significant 10 difference in transduction between FGF2-phage and control phage when FGF2 is attached to the phage via an avidin biotin linkage. In this case the biotinylated FGF2 is in excess of the FGF2 displayed on the phage surface such that internalization is expected to be primarily via the biotinylated FGF2. These data demonstrate specific receptor mediated transduction of mammalian cells by filamentous phage that 15 genetically display a targeting ligand (FGF2).

#### EXAMPLE 6

##### CONSTRUCTION OF A REPORTER GENE AND A DRUG RESISTANCE GENE IN PHAGE DISPLAY VECTORS

20 A GFP expression cassette consisting of the GFP gene (Cormack *et al.*, *Gene* 173:33-37, 1996) under control of a CMV promoter, a neomycin phosphotransferase gene under control of the SV40 early gene promoter, and an SV40 origin of replication are cloned into a gene III phagemid vector such as 25 pCANTAB 5E using standard methods (Sambrook *et al.*, *Molecular Cloning : A Laboratory Manual*, Cold Spring Harbor Press, 1989). The resulting phage is designated pmaM13. The same phagemid genome also containing FGF2-3 fused to gene III is designated pFGF-maM13. Similar constructs are also made with M13 30 phage type3 and type 33 and gene VIII phagemid and phage vectors. Recombinant phage displaying FGF2 on the coat and carrying the mammalian expression cassettes

including the SV40 replication origin are prepared by phagemid rescue with M13K07 (or suitable helper phage) are added to COS cells as described above. GFP expression is detected by fluorescence microscopy, fluorometry, and flow cytometry at 48-96 hours after phage addition. Drug resistant cells are selected with G418.

5

#### EXAMPLE 7

##### SELECTION OF FGF2-EXPRESSING PHAGE FROM A MIXED POPULATION

A M13 phage display library of random or unknown sequences is  
10 spiked with pFGF-maM13 phage. The mixture is used to infect COS cells as described above. The cells are washed extensively to remove non-specifically bound phage. Cells are re-plated 48-96 hours later at a 1 to 10 dilution and grown in G418 to select only cells that receive the transducing phage gene. Alternatively, the GFP expressing cells are isolated by flow cytometry using an excitation wavelength of 488  
15 and emission wavelength of 510.

DNA is extracted from G418-resistant cells and the FGF2 sequence is amplified. The amplification primers have sequences complementary to phage sequences located on each side of the FGF2 sequence in the gene III coding sequence. Detection of the FGF2 sequences in selected COS cells that are infected with a  
20 mixture of phage where the pFGF-maM13 phage is diluted at least 1:10,000 with the random sequence phage library demonstrates feasibility of the technique.

#### EXAMPLE 8

##### IDENTIFICATION OF FGF2 VARIANTS FOR IMPROVED GENE DELIVERY

25

A library of shuffled FGF2 mutants is created using the gene shuffling method described by Stemmer (*supra*). The FGF2 gene is amplified by PCR and fragmented by DNase 1 treatment. The fragments are reassembled using PCR in the absence of primers. The reassembled gene is cut with the appropriate restriction  
30 enzymes and cloned into an M13 phage vector such that the FGF mutants are fused



in-frame with the pIII coat protein gene. The phage vector contains a CMV promoter driven GFP reporter gene and an SV40 origin of replication. Several individual phage clones are sequenced to confirm that an average of 3 mutations per phage have been generated during the reassembly process. The resulting phage library of FGF2 mutations is amplified by standard protocols. The target cell line, BOS (BHK with T-Ag) is incubated with the library such that each member of the library is at an m.o.i. of at least 10. Accordingly,  $10^{11}$  phage representing  $10^6$  copies of  $10^5$  individual phage species are applied to  $10^5$  cells. The phage are incubated with the cells in PBS supplemented with 2% fetal bovine serum for 1-3 hours, after which non-binding phage are removed by extensive washing with PBS. Media is added and the cells returned to the incubator at 37° C to allow phage internalization.

#### EXAMPLE 9

##### SCREENING LIBRARIES FOR GENE DELIVERY LIGANDS

15

If the source of the desired ligand is not known, random peptide libraries or a cDNA library from placenta is used as a starting point for cDNA library screening. The library is amplified in the maM13-33 phage by infecting DH5 $\alpha$ F' (or other suitable host) bacteria, growing the culture overnight at 37°C and isolating the phage from the culture medium using standard protocols. A cDNA library containing  $10^5$  members has each member represented  $10^6$  times in a typical phage titer of  $10^{11}$  colony forming units/ml. The amount of phage used to infect is adjusted to the complexity of the library.

The completed maM13 phage library is screened against the target tissue or cell line. Screening can be performed *in-vitro* or *in-vivo*. The criteria for a positive "hit" is that the phage must be able to bind, be internalized, translocate to the nucleus, uncoat and replicate and express the genomic DNA containing the reporter gene in the target cell. Thus, only transduced target cells are selected either by GFP expression and cell sorting or drug resistance. Screening is performed directly against the target cells with no prescreening or enrichment. Enrichment for cell

binding is performed if no hits are found in the initial screen. A prescreen to select out phage that bind non-specific cells surface proteins is performed to reduce non-specific hits or if there are too many initial hits. Infection of at least  $10^7$  target cells is performed with at least  $10^{11}$  phage. The cells are incubated for at least 2 hours in PBS  
5 and washed extensively as described by Barry (Barry *et al.*, *Nature Med.*, 2:299-305, 1996). The cells are incubated in media at 37°C for 48-96 hours and selected in the appropriate drug (e.g., G418) for 7-14 days or until resistant colonies are visible microscopically. Drug resistant colonies are pooled, and the selected cDNAs amplified and subcloned back into the maM13-33 phage vector using PCR and  
10 standard molecular biology methods. Alternatively individual colonies are screened. Representative phage clones are sequenced to identify potential gene delivery ligands. Repeated rounds of infection and selection are performed to reduce the complexity of the selected clones. More stringent screening conditions such as increased selective drug concentrations or FACS sorting or the strongest fluorescent cells are performed  
15 in the later screens to select the most highly efficient gene delivery ligands from the initial screening.

Screening *in-vivo* is performed using methods previously described by Pasqualini for targeting organs or xenograft tumors using phage displayed peptides (Pasqualini, R. *et al.*, *Nature Biotechnology*, 15, 542-546 (1997); Pasqualini, R. *et al.*,  
20 *Nature*, 380, 364-366 (1996)) except that the organs or tumors are examined for reporter gene expression instead of the presence of phage. The phage library is injected intravenously into mice and organs or tumor samples tested for reporter gene function at 48-96 hours after injection. Tumor cells are cultured in G418 or FACs sorted (for GFP expression) to enrich for cells that express the phage transducing  
25 gene. The ligand encoding sequences are amplified from selected cells using PCR as described for *in-vitro* screening. As in *in-vitro* screening, repeated rounds of infection and rescreening are performed at increasing screening stringency to obtain the most efficient gene delivery ligands.

EXAMPLE 10

## IDENTIFICATION OF LIGANDS THAT TARGET COLON CARCINOMA

5 peptides is inserted into a filamentous phage genome such that the peptides are fused to the C-terminus of intact pIII coat proteins. A type 3 phage vector that only contains one copy of the pIII gene is used and, therefore, all of the pIII protein that is made will be fused to a peptide. Thus, 3-5 copies of a peptide is displayed on each phage. To simplify the screening the complexity of the library is first reduced by  
10 screening it for internalizing peptides. Peptides that facilitate the internalization of phage into a colon carcinoma cell line are isolated through several rounds of selection. The phage library is incubated with the cells for 3 hours at room temperature. The cells are washed extensively in PBS. A brief proteinase K treatment is used to inactivate phage that adhere to the cell surface. The cells are then  
15 lysed and cell lysates incubated with host bacteria. Internalized phage are amplified in bacteria and subjected to 4 or more iterations of exposure to cells and recovery of internalized phage. Replicative form DNA is prepared from the resulting sublibrary of internalizing phage. The random sequences in the sublibrary are subcloned into a phage vector MEGFP2 that contains a copy of the CMV driven reporter gene (GFP)  
20 and an SV40 replication origin. MEGFP2 differs from MEGFP3 (Figure 1A) in that the ori-CMV/EGFP expression cassette is in the reverse order, EGFP is followed by an SV40 polyadenylation site instead of Bovine Growth Hormone poly A, and the vector contains three additional Nco I sites within the ori-CMV/EGFP expression cassette.

25 The resulting CMV-GFP modified sublibrary is incubated with the HOS-116 recipient cell line such that each member of the library is represented at least  $10^6$  times. Thus, for example, a library with  $10^5$  members is added to  $\sim 10^5$  cells at a titres of  $\sim 1 \times 10^{11}$  yielding an m.o.i. for each member of at least 10. The phage are incubated with the cells in PBS supplemented with 2% fetal bovine serum for 1-3  
30 hours, after which non-binding phage are removed by extensive washing with PBS.

Media is added and the cells returned to the incubator at 37° C to allow phage internalization.

### EXAMPLE 11

#### 5 RECOVERY OF LIGAND ENCODING SEQUENCES FROM REPLICATIVE PHAGE

At 72 hours following the addition of the phage library. The target cells are removed from the plate and sorted for GFP expressing cells by FACS. The positively sorted cells are lysed and treated with proteinase K. The proteins are  
10 extracted with phenol/chloroform (24:1 solution) and nucleic acids precipitated in ethanol. The resulting DNA is resuspended in S1 nuclease buffer and treated with S1 nuclease to remove non-replicative single strand phage DNA. The DNA is again extracted with phenol/chloroform, precipitated, and resuspended in polymerase chain reaction buffer. Alternatively, nuclei are prepared from the positive cells, proteinase  
15 K treated and the lysate used directly in the PCR reaction. In either case, an equivalent number of negatively sorted cells are treated in parallel and used in the PCR reaction to monitor the enrichment of replicative phage DNA (double-stranded) over non-replicative phage DNA (single stranded) such that there is no phage DNA amplified in the samples from GFP negative cells. If phage DNA is amplified from  
20 negatively sorted cells then conditions must be made more stringent for the removal of single stranded phage DNA such as increasing treatment with S1 nuclease or further purification of nuclei through repeated sucrose step gradient purification or other suitable methods known for purification of nuclei (to remove non-replicative phage). These conditions might need to be determined empirically for each cell line  
25 and library used.

The phage sequence(s) encoding the ligand peptide is amplified using an appropriate set of oligonucleotide primers that flank the ligand encoding DNA sequence inserts that is fused to the pIII gene. These amplified inserts are recloned into the parent phage vector to create a sub-library of phage enriched now for gene  
30 delivery ligands for the target colon carcinoma cell line. Sequencing is performed on

representative clones to determine the complexity. The screening process is reiterated until the complexity is reduced sufficiently to identify one or more targeting ligands.

### EXAMPLE 12

#### SECOND GENERATION SCREENING OF PEPTIDES

5

Peptides are selected which have been previously identified from a random library by one or more panning or screening procedures using conventional vectors and panning methods (see Kay *et al.*, *Phage Display of Peptides and*  
10 *Proteins: A Laboratory Manual*, Academic Press, 1996). The DNA encoding the selected peptides is inserted as a fusion to the pIII coat protein in the MEGFP2 vector containing the GFP reporter gene cassette.

An M13 phage random peptide library is screened for peptides that bind and internalize in an FGF receptor overproducing cell line, Flg37 (an FGFR1  
15 stable transfectant of L6 cells (available from the ATCC; Manassas, VA) obtained from Dr. Murray Korc, UCI; Irvine, CA). In addition, such a cell line may be easily created by those skilled in the art. Following 5 rounds of panning and rescreening the complexity of the library is reduced such that 80% of the phage are represented by a single peptide-pIII fusion. The resulting peptide, FL5, has the sequence  
20 FVPDPYRKSR (SEQ ID NO: 1). The same library is also screened against Flg37 cells by selecting infective phage particles that internalize and associate with nuclei and cytoskeletal proteins. The 2 predominant peptide sequences identified by this screen after 5 rounds of panning are FN5A, CGGGPVAQRC (43%) (SEQ ID NO: 2) and FN5B, CLAHPHGQRC (34%) (SEQ ID NO: 3).

25 Oligonucleotides encoding the 3 peptides are inserted into the MEGFP vector as fusions to the pIII coat protein. The resulting phage are used to transfect COS cells. Phage are added to cells and incubated overnight at 37 °C in medium with 10% fetal calf serum. The cells are washed to remove unbound phage and returned to the incubator. Transduction is assessed by counting GFP expressing  
30 autofluorescent cells at 72 hours after the addition of phage. The results (Figure 5 are

that a greater transduction efficiency is observed with FL5 than FN5A or FN5B indicating that FL5 is a more efficient as a gene transfer ligand in this system. The transduction screening method as a second generation screen is capable of distinguishing among peptides that were selected by different primary cell based  
5 screens.

### EXAMPLE 13

#### EGF MEDIATED MAMMALIAN CELL TRANSDUCTION

10           Epidermal growth factor displaying phage were constructed as described above for FGF displaying phage. Western blot analysis demonstrates that EGF was efficiently expressed on the phage coat in a multivalent manner (Figure 6). Phage were prepared for Western analysis by obtaining the EGF-phage from cultures of infected host bacteria and purified by PEG precipitation and CsCl gradient  
15 centrifugation. The phage particle proteins were then separated by gel electrophoresis and blotted onto a nitrocellulose membrane. Blots were then probed with either anti-EGF or anti-pIII antibody (mouse anti-human EGF, Biosource International; Camarillo, California) or anti-pIII antibody (mouse anti-pIII, MoBiTech; Germany) followed by HRP-goat-anti-mouse (Jackson Laboratories, USA).

20           Following the procedures detailed above, EGF-phage were screened for their ability to effectively transduce COS cells. Briefly, EGF-phage were incubated with COS cells (~75,000 cells/well) for 72 hours with a variety of phage titers. As demonstrated by Figure 7 the optimal dose was  $10^{10}$  pfu/ml which resulted in the highest transduction efficiency with almost no non-specific transduction by  
25 untargeted phage. Transduction efficiency also increases with longer incubation times. As demonstrated in Figure 8 when EGF-phage were incubated with COS cells (~75,000 cells/well) at  $10^{11}$  pfu/ml for various times and subsequently measured for GFP expression at 72 hours, longer incubation times increased transduction efficiency.

Further, specificity of EGF-phage mediated COS cell transduction was determined by incubating EGF-phage with excess ligand. As depicted in Figures 9A and 9B, COS cells incubated with  $10^{11}$  pfu/ml of phage for 72 hours with or without excess ligand or untargeted phage demonstrate that targeting is due to the presence of the ligand.

#### EXAMPLE 14

##### SIMULTANEOUS IDENTIFICATION OF INTERNALIZING LIGANDS AND ANTI-LIGAND BINDING TARGETS

10

To identify internalizing ligand-anti-ligand binding target interactions, the putative ligand is displayed on the surface of filamentous phage that carry a mammalian reporter gene expression cassette. The candidate binding target peptides/proteins are expressed on the surface of COS cells by substituting the target cDNA for the extra cellular domain encoding DNA portion of the EGF receptor in a suitable mammalian cell expression vector (*i.e.*, pcDNA 3.1; Invitrogen, CA).

To accomplish this, a library of cDNAs is inserted into a mammalian expression vector (pcDNA 3.1) such that the cDNAs are fused to the transmembranes and intracellular domains of EFG receptor cDNA. DNA is prepared from individual or pools of bacterial clones that have been transformed to carry the cDNA-receptor fusion protein expression plasmid. COS cells are transfected with the resulting plasmid DNAs in six well plates at low density. At 24 hours later, ligand display phage carrying the CMV driven reporter gene GFP are added to the transfected COS cells.

Binding of the phage displayed ligand to the cell surface display binding target (*i.e.* protein - EGF receptor fusion protein), results in dimerization of the receptor and subsequent internalization of phage that display the binding ligand. The internalized phage are trafficked to the nucleus where the reporter gene is expressed. 72 hours after adding phage, cells expressing the reporter gene are selected by FACs. cDNAs encoding reactive peptides are identified by the presence

of GFP positive cells in the COS transfectants for each cDNA or cDNA pool. The binding ligand is identified by PCR amplification and sequencing of the phage ligand-pIII fusion gene. The target peptide is identified by PCR amplification and sequencing the peptide-EGF receptor fusion protein from the selected cell(s).

5

### EXAMPLE 15

#### IDENTIFICATION OF CELL TARGETS

Phage that display a ligand as a pIII fusion on the phage coat and carry the GFP expression cassette are prepared using standard protocols, as discussed above. Control phage that carry GFP but don't display a ligand are also prepared. Candidate cell targets are seeded into 6 well culture plates at about 40,000 cells/well. At 24 hours after seeding cells, phage are added at  $\sim 10^{10}$  pfu/ml. The plates are incubated at 37°C for an additional 72 hours. Each cell well is scored by counting GFP positive autofluorescent cells. The cell types that have a ratio of GFP positive cells in the ligand-phage treated well/control phage treated cells of greater than 1.0 are selected as targets for further study and characterization. As an alternative to GFP, a drug resistance gene can be used in which case after 72 hours the cells are allowed to continue growth in selective medium containing the drug. Positive cell types are scored by counting wells that have drug resistant colonies.

Carcinoma cell lines which are known to express EGF were screened by the above method using EGF-phage and compared to the control endothelial cell line which is EGF receptor negative (Cell lines obtained from ATCC, Manassas, VA and grown under standard ATCC culture conditions). As shown in Figure 10, the carcinoma cell lines derived from various tissues were differentially transduced while the receptor negative, endothelial cells displayed no transduction. Accordingly, identification of target cells or tissues can be accomplished using these methods.



### EXAMPLE 16

#### IDENTIFICATION OF PATHOGEN TARGET CELLS

Ligand display phage are constructed as discussed above, with the  
5 ligand being full-length or fragments of coat or envelope proteins of a known or  
suspected pathogen. The ligand expressed on the display phage coat can be expressed  
from the cDNA or cDNA derivative of the coat or envelope protein of a known or  
suspected pathogen (*e.g.*, HIV envelope protein gene). The envelope gene is  
randomly fragmented to form a library of display phage display distinct portions of  
10 the coat protein. Thereby allowing determination of the portion of the gene that  
encodes a protein that functionally interacts with the host cell surface receptors  
allowing internalization. Smaller pathogen coat proteins are displayed in entirety.  
The pathogen coat display phage acts as surrogate pathogen with the advantage of  
providing a simple assay for detection of host cells. Phage displaying coat protein are  
15 screened against various cell types *in vitro* as described above or *in vivo* by injection  
and subsequent identification of target cells and tissues by fluorescent microscopy,  
FACS analysis to detect GFP, or growth in selective medium to detect expression of a  
drug resistance marker.

20

### EXAMPLE 17

#### IDENTIFICATION OF PATHOGEN LIGANDS

The gene(s) or portion of a gene that interacts with the host cell  
surface receptor to allow internalization is identified by making a phage display  
25 library of the cDNAs expressed by the pathogen or of the pathogen genome or  
fragments of the genome. The display library phage vector carries the GFP or  
suitable reporter gene driven by the mammalian promoter, as described above. The  
libraries are then screened against a known or putative host cell types by detecting  
transgene expression (*i.e.*, drug selection or other detectable marker). Once cells are

identified, the sequence of the nucleic acid encoding the internalizing ligand is determined by PCR sequencing of the pIII-putative ligand fusion construct.

#### EXAMPLE 18

##### 5 IDENTIFICATION OF SECRETED AND INTERNALIZING LIGANDS FOR TUMOR CELLS

Tumor cells interact with surrounding host stromal and other cell types via chemo-attractants and other factors which, for example, stimulate the stromal cells to secrete factors that support tumor growth (*i.e.*, VEGF). To investigate these  
10 interactions, a library of putative secreted ligand cDNAs is prepared from tumor cell mRNA and selected by methods known in the art such as epitope-tagging, Sloan *et al.*, *Protein Expression and Purification* 11:119-124, 1997. The secreted protein encoding cDNAs are inserted into the reporter phage vector as described above.

Individual phage clones or pools of phage clones are screened against  
15 various stromal cell types to identify cell types that are targets for tumor cell secreted factors, and to identify the secreted factors. The inverse strategy can also be applied by screening a library of, for example, fibroblast or other stromal cell secreted protein encoding cDNAs for factors that bind and internalize into various tumor cell types.

#### EXAMPLE 19

##### 20 SELECTION OF EGF-EXPRESSING PHAGE FROM A POPULATION OF NON-TARGETED PHAGE

Non-targeted M13 phage was spiked with EGF-phage. The mixture  
25 was used to infect COS cells and incubated for 72 hours, as described above. The cells are washed extensively to remove non-specifically bound phage. The GFP expressing cells are isolated by flow cytometry (FACS) using an excitation wavelength of 488 and emission wavelength of 510.

DNA is extracted from GFP positive cells and the EGF sequence was  
30 amplified by PCR. The amplification primers have sequences complementary to

phage sequences located on each side of the EGF sequence in the gene III coding sequence. These sequences were re-cloned into the phage vector and new phage were prepared for subsequent rounds of selection.

Briefly, the following biotinylated oligonucleotides were used to  
5 amplify the ligand gene III fusion:

Anchor1M8f 48 5'Bio AAAGGATCCGGGTTCCTCGGTGGGCGATGGTTGTTGTCATTGTCGGC  
M3rev2 25 bio CCGTAACACTGAGTTTCGTCACCAG

10 However, the following have also been used with success:

M8for2b 30 biotin GCGTGGGCGATGGTTGTTGTCATTGTCGGC  
m3revB 25 biotin CCACAGACAACCTCATAGTTAGCG

Proteinase K treated nuclear preparations of FACsorted COS cells.

15 PCR is carried out using Clontech's Advantage GF polymerase mix and cycled under the following conditions:

1 cycle:  
94°C 1 min.

20 40 cycles:  
94°C 20 sec.  
60°C 20 sec.  
72°C 20 sec.

25 Following amplification, duplicate samples were combined and purified using Qiaquick columns (Qiagen Inc., Valencia, CA). The PCR products were then digested with NcoI and PstI restriction endonucleases. While SA-magnetic beads or other means for removal of "ends" of fragments increases ligation efficiency, such removal is not required. The digestion product is ligated into a new phage  
30 vector and used to transform competent cells by electroporation.

After sub-cloning and electroporation of bacterial cells, the bacteria were plated in top agar and grown overnight at 37°C, plaques were selected from plates and analyzed via PCR using oligonucleotides as follows:

MANPgIII 20 TTTTGGAGATTTTCAACGTG

MANPgIIIr      20      TGCTAAACAACCTTTCAACAG

However, the oligonucleotides listed previously above, are equally useful.

5                      As demonstrated in Figure 11, enrichment of targeted EGF-phage from 0.1% to 100% EGF-phage was complete after 3 rounds of selection and enrichment from 0.0001% to 100% EGF-phage was complete after 4 rounds of selection. Accordingly, this experiment demonstrates the ability to select a specific ligand expressing phage from a population at dilutions of  $1:10^3$  and  $1:10^6$ . In  
10 addition, while further diluted ligand expressing phage can be detected, further rounds of selection may be necessary.

#### EXAMPLE 20

##### 15                      CREATION OF A SUB-LIBRARY OF PEPTIDES THAT ARE INTERNALIZED AND TRAFFICKED TO THE NUCLEUS

Phage that display a candidate ligand as a pIII or pVIII fusion on the phage coat are prepared using standard protocols, as discussed above. In the present experiment a phage library (MANP-TN10, Dyax, Corp.) is used. COS cells are  
20 plated on 2X10 cm plates at about 105,000 cells/plate. At 24 hours after seeding cells, phage are added at  $\sim 10^{10}$  pfu/ml. The plates are incubated at 37°C for an additional 72 hours. The cells are then harvested in Trypsin-EDTA and pelleted. The cells are re-suspended in 0.5 ml of PBS and under-layered with 0.5mls of nuclear isolation buffer (NIB) and spun at 200 x g for 8 minutes at 4°C (NIB=40% Sucrose,  
25 0.1% DMSO, 2% NP40, 1.6% Triton X-100, 0.2mM AEBSF (4-(2-Aminoethyl)benzenesulfonyl Fluoride, in PBS). The pellet is then re-suspended in 400  $\mu$ l 1%NP40 and under-layered with 40% sucrose and again spun at 200 x g for 8 minutes at 4°C.

The pellet is then re-suspended in 100  $\mu$ l PKB (Proteinase K Buffer--  
30 50 mM Tris-HCl pH 8.5, 1 mM EDTA, 0.5% Tween-20). 1.4  $\mu$ l of PK (Proteinase K from Boehringer Mannheim, 14mg/ml) is added and incubated at 55°C for 3 hours,

- then heated to 95°C for 15 min. The DNA is then pelleted at maximum speed in a microfuge and washed 1 time with 70% ethanol followed by air drying in a hood. The resulting pellet is resuspended in a 20µl of 10mM Tris pH 7.2 and the ligand gene III fusion is amplified as described in Example 19, above, except that the
- 5 cycling program was adjusted as follows:

1 cycle:  
94°C 1 min.

- 10 25 cycles:  
94°C 20 sec.  
60°C 20 sec.  
72°C 20 sec.

- Following amplification, the product was purified using a Qiaquick
- 15 column (Qiagen) followed by digestion using NcoI and PstI restriction enzymes, as described above. Biotinylated fragments are removed using streptavidin conjugated beads (Promega Corp., Madison, WI), and the resulting sample is ethanol precipitated. The precipitated DNA is then washed and re-suspended in 10 µl of 10mM Tris pH 8.5 and ligated into the reporter gene carrying phage vector.
- 20 Following ligation the DNA is ethanol precipitated, washed, and used to transform competent cells (Stratagene electrocompetent cells Xl1Blue MRF'). Phage selected for in this manner (TN10nuclear selection) are then compared to non-selected phage (TN10library). The comparison of the pre-selected pool demonstrates that a significant population of the library which did not internalize has been removed in
- 25 one round of screening, see Table below:

Phage Prep	In/Out	Dilution factor	µl plated	plaques	Titer (pfu/ml)	Vol of prep (µl)	Phage recovered	Fraction of input
TN10 library	In	8	100	123	1.23E+08	5000	6.15E+11	
TN10 nuclear	Out	0	10	127	1.27E+01	400	5.08E+03	8.26E-09

### EXAMPLE 21

#### LIGAND SELECTION VIA NUCLEIC ACID BINDING DOMAINS

A phage library comprising a number of ligand displaying phage are  
5 created using a lac operon containing phagemid. The phagemid can be either a  
reporter gene containing phage (e.g., MEGFP3) or a non-reporter gene containing  
phagemid (e.g., any vector containing a phage origin of replication, such as  
pCOMB3, pBS+, pCR, and the like). The MEGFP3 vector has been modified with a  
mammalian expression cassette designed to express the reporter gene GFP to monitor  
10 mammalian cell transduction by the phage. Other vectors include pCANTAB 5 E  
(Pharmacia Biotech; Piscataway, NJ) or M13 type 3 or 33 for gene III fusions (see  
Kay *et al.*, Phage Display of Peptides and Proteins: A Laboratory Manual,, Academic  
Press, 1996; McConnell *et al.*, *Mol. Divers.* 1:165-176,1996). Similarly, the ligand  
library is cloned into M13 type 8 or 88 vector for fusion to the gene VIII protein  
15 (Roberts *et al.*, *Methods Enzymol.* 267:68-82, 1996; Markland *et al.*, *Gene* 109:13-19,  
1991).

Candidate cell targets are seeded into 6-well culture plates at about  
40,000 cells/well. At 24 hours after seeding cells, phage are added at  $\sim 10^{10}$  pfu/ml.  
The plates are incubated at 37°C for an additional 72 hours. Following incubation  
20 with the phage library, the target cells are removed from the plate and sorted for GFP  
expressing cells by FACS or directly lysed and the nucleic acid purified by passing  
over a sepharose 4B DNA affinity-column having conjugated thereto the lac repressor  
protein. Prior to affinity purification the cells are lysed and a nuclear extract is  
produced by following standard procedures, such as those described by Cull *et al.*,  
25 *Proc. Nat'l. Acad. Sci. USA* 89:1865-1869, 1992; Schatz *et al.*, *Methods in*  
*Enzymology* 267:171-191, 1996). The nuclear extract is then passed over the affinity  
column.

After applying to the column, the column is washed extensively with  
loading buffer (20mM Tris-HCl pH 7.2) and eluted with a salt gradient. The resulting  
30 DNA containing fractions are pooled, amplified by PCR using the flanking gene III

or gene VIII fusion sequences as primer templates, and subcloned back into a phagemid vector for further rounds of enrichment or alternatively for direct sequence characterization.

5

### EXAMPLE 23

#### INTERNALIZED LIGAND SEQUENCE AMPLIFICATION BY SV40 SHUTTLE VECTOR TRANSDUCTION

The phagemid-shuttle vector includes the SV40 origin and packaging  
10 sequences, as well as SV40 capsid-encoding late genes under control of a promoter functional in target cells. This vector is created by PCR amplification of relevant sequences or direct restriction enzyme digestion and sub-cloning. These sequences can be obtained from commercially available vectors or wild-type virus. Similarly, the phage coat protein fusion, the phage origin and packaging sequences, and  
15 bacterial selection markers can be assembled from current phage vectors.

Phage particles expressing a library of ligands as genetic fusions on the coat proteins (gIII or gVIII) are generated by rescuing phagemid containing bacteria with a helper phage, such that the phagemid genome is packaged into the phage particle expressing the ligand which is encoded by that genome. A target cell  
20 line containing the SV40 T antigens (either transfected or provided in trans with the VP22 fusion protein as a delivery vehicle) is incubated with the phage particles. Those particles expressing the appropriate ligands deliver the phagemid DNA to the nucleus. Due to the presence of the large T antigen in the cells and the SV40 origin, the DNA replicates. The dsDNA is then packaged into SV40 viral particles due to the  
25 presence of the capsid proteins encoded by the SV40 genes also carried on the phagemid genome. The SV40 particles carrying the phagemid then infect other neighboring cells and thus amplifying the internalized ligands until the whole population of cells is infected. Eventually, in all permissive cells are lysed due to viral production. Viral particles are harvested from the supernatants and the DNA

they contain is analyzed by sequencing to determine the sequence of the ligand responsible for the initial internalization.

#### EXAMPLE 24

##### 5        ENHANCEMENT OF TARGET CELL TRANSDUCTION USING HEAT SHOCK AND/OR          GENOTOXIC TREATMENT

         The effects of heat shock and another genotoxic treatment, camptothecin were tested. Camptothecin is a type I topoisomerase inhibitor that  
10       produces DNA strand breaks. Camptothecin is found to enhance transduction efficiency up to 2 fold at 0.1  $\mu$ M but was inhibitory at higher concentrations (data not shown). EGF displaying phage (MG4-EGF vector) were incubated with COS cells for 24 hours at which time the cells were either not further treated, subjected to a four hour heat shock (42.5°C), or treated with 0.1  $\mu$ M camptothecin for four hours. GFP  
15       autofluorescent cells were counted at 72 hours after addition of phage. As depicted in Figure 14 the results indicate about a 2 fold enhancement of targeted phage mediated transduction with either heat shock or camptothecin. The combination of both treatments resulted in a modest synergistic increase in efficiency over either treatment alone.

20

#### EXAMPLE 25

##### ENHANCEMENT OF TRANSDUCTION UTILIZING          ENDOSOMAL ESCAPE PEPTIDE DISPLAY

25       The addition of endosomal escape peptides that are derived from minimal peptide sequences needed for viral endosome escape have been shown to enhance non-viral delivery of condensed DNA (Sosnowski *et al.*, *J. Biol. Chem.* 271:33647-33653, 1996). Accordingly, such endosomal sequences were tested with the ligand display system described herein. Endosomal escape peptide fusions to pIII  
30       that are in-frame with both the EGF gene and the pIII gene were constructed. The



sequence MAEGLFEAIEGFIENGWEGMIDGWYG (adapted from the INF7 N-terminal sequence of the influenza virus X-31 hemagglutinin subunit HA-2) was added to the N-terminus of EGF in MG4-EGF or pIII in MG4. This sequence is identical to the endosome disruptive peptide (INF7) described by Plank *et al.* (*J. Biol.*  
5 *Chem.* 269:12918-12924, 1994) except for the addition of the MAE tripeptide at the N-terminus. It is encoded on 2 overlapping oligonucleotides that are annealed and ligated into the NcoI site in the MG4 and MG4-EGF vectors.

The INF7 containing phage were tested on COS cells to determine transduction efficiency. The results (Figure 15) show that transduction efficiency is  
10 increased about 1.8 fold with the addition of the INF7 sequence relative to the unmodified MG4-EGF phage. The addition of the INF7 sequence in the control phage has no effect on the background levels of transduction observed when transfecting COS1 cells with this phage at a titer of  $10^{11}$  pfu/ml. Thus, an endosomal disruptive peptide enhances the ability of targeted phage to transduce COS1 cells  
15 when presented on the N-terminus of the EGF-pIII coat fusion protein.

#### EXAMPLE 26

##### ENHANCEMENT OF TRANSDUCTION UTILIZING ENDOSOMAL ESCAPE PEPTIDE DISPLAY AND HEAT SHOCK

20

The effect of both heat shock and the addition of an endosomal escape peptide were tested in combination to determine whether they effect distinct aspects of the transduction pathway and to test the limits of phage mediated transduction. EGF-phage (MG4-EGF), EGF-phage co-displaying an endosomal escape peptide  
25 (INF7 as above) (MG4-EGF-EE) or control phage (MG4) were added to COS1 cells at a titer of about  $10^{11}$  pfu/ml and incubated for 72 or 96 hours. Cells were subjected to a seven hour heat shock (42.5°C) at 40 hours after phage addition. The percentage of GFP positive cells was determined by FACS analysis. The results (Figure 16) show that the effects of heat shock (HS) and the addition of the endosomal escape  
30 (EE) sequence are additive. At 72 hours after phage addition, the combination of HS

and the EE sequence results in transduction efficiency of 3.5% and at 96 hours in about 11% transduction efficiency. At both time points the addition of the EE peptide results in about 2X the efficiency compared to heat shock alone. The highest transduction efficiency we observe in the absence of HS or the EE peptide is about 2% at 96 hours.

### EXAMPLE 27

#### CONSTRUCTION OF DUAL DISPLAY VECTOR

The pIII/pVIII dual display vector is constructed by the insertion of a pVIII encoding open reading frame down stream from the stop codon of pIII in a pIII-fusion phagemid vector (*e.g.*, pUC-MG4 (Figure 17)). This is accomplished by amplifying the mature gVIII gene from MG4 phage using primers that contain EcoRI restriction endonuclease extensions on their ends.

The DNA sequence encoding the Eco RI insert for making dual display vector encodes the pEL B Signal Peptide and gVIII gene with restriction enzyme sites Sst II, XhoI and BamHI for insertion of peptide fusion s to gene VIII.

#### DNA

GAATTCATGAAATACCTATTGCCTACGGCCGCAGCAGGTCTCCTCCTCTTA  
GCAGCACAACCAGCAATGGCCGCGGAGTGACTCGAGGATCCCGCAAAAG  
CGGCCTTTAACTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTATGCG  
TGGGCGATGGTTGTTGTCATTGTCGGCGCAACTATCGGTATCAAGCTGTTT  
AAGAAATTCACCTCGAAAGCAAGCTGATAAGAATTC

#### Protein translation:

**MKYL**LPTAAAGLLLLAAQPAMAAE.LEDPAKAAFNSLQASATEYIGYAWA  
MVVVIVGATIGIKLFFKKFTSKAS

“.”= STOP CODON

pEL B leader is in bold type

The forward primer contains an additional extension that encodes the pelB secretion signal peptide (Power *et al.*, *Gene* 113:95-99, 1992) and restriction sites (SstII, XhoI, BamHI) for insertion of peptide or protein encoding fusions in-frame with the pVIII gene. There is an in-frame stop codon at the 5' end of the pVIII gene such that no pVIII protein is translated unless a peptide or protein encoding sequence is inserted in-frame near the sequences encoding the N-terminus of pVIII. The resulting PCR product is digested with EcoRI and inserted into the EcoRI site of the phagemid vector forming a bicistronic message encoding pIII followed by pVIII, both of which are regulated by the lac promoter upstream from the 2 consecutive open reading frames. (See Figure 18)

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

## CLAIMS

We claim:

1. A method of selecting internalizing ligands displayed on a genetic package, comprising:
  - (a) contacting one or more ligand displaying genetic packages with a cell(s), wherein each package carries a gene encoding a detectable product which is expressed upon internalization of the package, and
  - (b) detecting product expressed by the cell(s); and  
thereby selecting internalizing ligands displayed on a genetic package.
2. The method of claim 1, further comprising isolating the cell(s) that express the detectable product.
3. The method of claim 2, wherein the cell(s) are isolated by flow cytometry.
4. The method of claim 2, further comprising recovering a nucleic acid molecule encoding a ligand from cell(s) expressing the product.
5. The method of claim 1, wherein the ligand displaying packages comprise a library of ligand displaying packages.
6. The method of claim 5, wherein the library is a cDNA library.
7. The method of claim 5, wherein the library is an antibody gene library.
8. The method of claim 5, wherein the library is a random peptide gene library.

9. The method of claim 5, wherein the library is a mutein library.
10. The method claim 1, wherein the detectable product is selected from the group consisting of green fluorescent protein,  $\beta$ -galactosidase, secreted alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, human growth hormone and neomycin phosphotransferase.
11. The method of claim 1, wherein the ligand displaying genetic packages comprise bacteriophage.
12. The method of claim 10, wherein the bacteriophage are filamentous phage.
13. The method of claims 11 or 12, wherein the bacteriophage carries a genome vector.
14. The method of claims 11 or 12, wherein the bacteriophage carries a hybrid vector.
15. The method of claim 14, wherein the hybrid vector comprises SV40 genome nucleic acid sequences.
16. A high throughput method of identifying an internalizing ligand displayed on a genetic package, comprising:
  - (a) contacting one or more ligand displaying genetic packages with a cell(s) in an array, wherein each package carries a gene encoding at least one detectable product which is expressed upon internalization of the package; and
  - (b) detecting product(s) expressed by the cell(s) in the array, and thereby identifying an internalizing ligand displayed on a genetic package.

17. The method of claim 16, wherein the ligand displaying package comprises a bacteriophage.

18. The method of claim 16, further comprising recovering a nucleic acid molecule encoding a ligand and/or an anti-ligand from the cells expressing the product.

19. The method of claim 16, wherein the ligand displaying package comprises a library of ligand displaying packages.

20. The method of claim 19, wherein the library is a cDNA library.

21. The method of claim 19, wherein the library is an antibody gene library.

22. The method of claim 19, wherein the library is a random peptide gene library.

23. The method of claim 19, wherein the library is a mutein library.

24. The method of claim 16, wherein the detectable product is selected from the group consisting of green fluorescent protein,  $\beta$ -galactosidase, secreted alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, human growth hormone and neomycin phosphotransferase.

25. The method of claim 17, wherein the bacteriophage are filamentous phage.

26. The method of claim 17, wherein the bacteriophage are lambdoid phage.

27. The method of claim 17, wherein the bacteriophage carries a hybrid vector.
28. The method of claim 27, wherein the hybrid vector comprises SV40 or AAV genome nucleic acid sequences.
29. The method of claim 17, wherein the bacteriophage carries a genome vector.
30. A method of identifying an internalizing ligand displayed on a genetic package, comprising:
- (a) contacting one or more ligand displaying a genetic packages with a cell(s), wherein each package carries a selectable marker which is detectable upon internalization of the package,
  - (b) detecting the selectable marker internalized by the cells; and
  - (c) recovering a nucleic acid molecule encoding an internalizing ligand from the cell(s) carrying the selectable marker, and
- thereby identifying an internalizing ligand displayed on a genetic package.
31. The method of claim 30, further comprising isolating cells that express the selectable product.
32. The method of claim 30, wherein the cells are isolated by flow cytometry.
33. The method of claim 30, wherein the ligand displaying packages comprise a library of ligand displaying packages.
34. The method of claim 33, wherein the library is a cDNA library.

35. The method of claim 33, wherein the library is an antibody gene library.
36. The method of claim 33, wherein the library is a random peptide gene library.
37. The method of claim 33, wherein the library is a mutein library.
38. The method of claim 30, wherein the selectable marker is selected from the group consisting of reporter gene expression, expression of a gene that confers the ability to permit cell growth under selection conditions, non-endogenous nucleic acid sequences that permit PCR amplification, and nucleic acid sequences that can be purified by protein/DNA binding.
39. The method of claim 30, wherein the ligand displaying genetic packages comprise bacteriophage.
40. The method of claim 39, wherein the bacteriophage are filamentous phage.
41. The method of claim 39, wherein the bacteriophage carries a genome vector.
42. The method of claim 39, wherein the bacteriophage comprises a hybrid vector.
43. The method of claim 42, wherein the hybrid vector comprises SV40 or AAV genome nucleic acid sequences.



44. A method of identifying a target cell or tissue for internalizing ligands, comprising:

- (a) contacting a library of ligand displaying genetic packages with a cell(s) or tissue(s), wherein each package carries a gene encoding a detectable product which is expressed upon internalization of the package; and
- (b) detecting product expressed by the cell(s) or tissue(s), and thereby identifying a target cell or tissue for internalizing ligands.

45. The method of claim 44, further comprising isolating cells that express the detectable product.

46. The method of claim 45, wherein the cells are isolated by flow cytometry.

47. A method of selecting an internalizing ligand for a selected target cell or tissue within a pool of target cells or tissues and identifying a target cell or tissue for the internalizing ligand, comprising:

- (a) contacting a library of ligand displaying genetic packages with a pool of cell(s) or tissue(s), wherein each package carries a gene encoding a selectable marker which is expressed upon internalization of the package;
- (b) detecting the selectable marker expressed by the cell(s) or tissue(s);  
and
- (c) recovering a nucleic acid molecule encoding an internalizing ligand from a selected set of cell(s) or tissue(s) within the pool expressing the selectable marker.

48. The method of claim 47, further comprising isolating cells that express the detectable product.

49. The method of claim 48, wherein the cells are isolated by flow cytometry.

50. The method of claim 47, wherein the selectable marker is selected from the group consisting of reporter gene expression, expression of a gene that confers the ability to permit cell growth under selection conditions, non-endogenous nucleic acid sequences that permit PCR amplification, and nucleic acid sequences that can be purified by protein/DNA binding.
51. The method of claims 44 or 47, wherein the target cells or tissues are arranged in an array to facilitate high throughput screening.
52. The method of claim 51, wherein the array contains more than one cell type or tissue type.
53. The method of claim 51, wherein the ligand displaying genetic package is a bacteriophage.
54. The method of claim 53, further comprising step (c), wherein the library of bacteriophages is repeatedly divided into subset pools and screened using steps (a) and (b) until a specific bacteriophage expressing an internalizing ligand is identified; thereby allowing identification of the internalizing ligand.
55. The method of any one of claims 44, 47, or 51, wherein the library comprises only known ligands.
56. The method of any one of claims 44, 47, or 51, wherein the library comprises at least one unknown ligand.
57. The method of claim 44, 47, or 51, wherein the library is a cDNA library.
58. The method of claim 44, 47, or 51, wherein the library is an antibody gene library.

59. The method of claim 44, 47, or 51, wherein the library is a random peptide gene library.

60. The method of claim 44, 47, or 51, wherein the library is a mutein library.

61. The method of claim 47, wherein the library is a pathogen coat or envelope gene library.

62. The method of any one of claims 44, 47, or 51, wherein the detectable product is selected from the group consisting of green fluorescent protein,  $\beta$ -galactosidase, secreted alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, human growth hormone and neomycin phosphotransferase.

63. The method of any one of claims 44 or 47, wherein the ligand displaying genetic packages comprise bacteriophage.

64. The method of claim 63, wherein the bacteriophage are filamentous phage.

65. The method of claim 63, wherein the bacteriophage carries a genome vector.

66. A method of selecting internalizing ligand/anti-ligand pairs, comprising:

(a) contacting one or more ligand displaying genetic packages with a cell(s), wherein each package carries a gene encoding a detectable product which is expressed upon internalization of the package, and wherein the cell expresses an anti-ligand-receptor fusion protein on its surface; and

(b) detecting product expressed by the cell(s), and thereby selecting internalizing ligand/anti-ligand pairs.

67. The method of claim 66, further comprising isolating the cell(s) that express the detectable product.

68. The method of claim 67, wherein the cell(s) are isolated by flow cytometry.

69. The method of claim 67, further comprising recovering a nucleic acid molecule encoding a ligand and/or a nucleic acid molecule encoding an anti-ligand from cell(s) expressing the product.

70. The method of claim 66, wherein the ligand displaying packages comprise a library of ligand displaying packages.

71. The method of claim 70, wherein the cells express a library of anti-ligand-receptor fusion proteins.

72. The method of claim 70 or 71, wherein the library is a cDNA library.

73. The method of claim 70 or 71, wherein the library is an antibody gene library.

74. The method of claim 70 or 71, wherein the library is a random peptide gene library.

75. The method of claim 70 or 71, wherein the library is a mutein library.

76. The method claim 66, wherein the detectable product is selected from the group consisting of green fluorescent protein,  $\beta$ -galactosidase, secreted alkaline

phosphatase, chloramphenicol acetyltransferase, luciferase, human growth hormone and neomycin phosphotransferase.

77. The method of claim 66, wherein the ligand displaying genetic packages comprise bacteriophage.

78. The method of claim 77, wherein the bacteriophage are filamentous phage.

79. The method of claims 77 or 78, wherein the bacteriophage carries a genome vector.

80. A method of identifying a ligand or anti-ligand of a internalizing ligand/anti-ligand pair, comprising:

(a) contacting one or more ligand displaying a genetic packages with a cell(s), wherein each package carries a gene encoding a selectable marker which is expressed upon internalization of the package, and wherein the cell(s) expresses an anti-ligand-receptor fusion protein on its surface;

(b) detecting the selectable marker expressed by the cell(s); and

(c) recovering a nucleic acid molecule encoding an internalizing ligand and/or a nucleic acid molecule encoding an internalizing anti-ligand from the cell(s) expressing the product, and

thereby identifying the ligand and/or anti-ligand of a internalizing ligand/anti-ligand pair.

81. The method of claim 80, wherein the selectable marker is selected from the group consisting of reporter gene expression, expression of a gene that confers the ability to permit cell growth under selection conditions, non-endogenous nucleic acid sequences that permit PCR amplification, and nucleic acid sequences that can be purified by protein/DNA binding.

82. The method of claim 80, further comprising isolating cells that express the detectable product.

83. The method of claim 82, wherein the cells are isolated by flow cytometry.

84. The method of claim 80, wherein the ligand displaying package comprise a library of ligand displaying packages.

85. The method of claim 80, wherein the cells express a library of anti-ligand-receptor fusions.

86. The method of claim 84 or 85, wherein the library is a cDNA library.

87. The method of claim 84 or 85, wherein the library is an antibody gene library.

88. The method of claim 84 or 85, wherein the library is a random peptide gene library.

89. The method of claim 84 or 85, wherein the library is a mutein library.

90. The method of claim 80, wherein the detectable product is selected from the group consisting of green fluorescent protein,  $\beta$ -galactosidase, secreted alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, human growth hormone and neomycin phosphotransferase.

91. The method of claim 80, wherein the ligand displaying genetic packages comprise bacteriophage.

92. The method of claim 91, wherein the bacteriophage are filamentous phage.
93. The method of claim 91 or 92, wherein the bacteriophage carries a genome vector.
94. The method of claims 66 or 80, wherein the target cells or tissues are arranged in an array to facilitate high throughput screening.
95. The method of claim 94, wherein the array contains cells expressing a library of anti-ligand-receptor fusion proteins.
96. The method of claim 94, wherein the ligand displaying package comprises a bacteriophage.
97. The method of claim 94, further comprising recovering a nucleic acid molecule encoding a ligand and/or an anti-ligand from the cells expressing the product.
98. The method of claim 94, wherein the ligand displaying package comprises a library of ligand displaying packages.
99. The method of claim 95 or 98, wherein the library is a cDNA library.
100. The method of claim 95 or 98, wherein the library is an antibody gene library.
101. The method of claim 95 or 98, wherein the library is a random peptide gene library.

102. The method of claim 95 or 98, wherein the library is a mutein library.
103. The method of claim 94, wherein the detectable product is selected from the group consisting of green fluorescent protein,  $\beta$ -galactosidase, secreted alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, human growth hormone and neomycin phosphotransferase.
104. The method of claim 96, wherein the bacteriophage are filamentous phage.
105. The method of claim 96, wherein the bacteriophage are lambdoid phage.
106. The method of claim 104 or 105, wherein the bacteriophage carries a genome vector.
107. The method of any one of claims 1, 16, 30, 44, 47, 66, or 80, further comprising contacting the target cells with a genotoxic agent.
108. The method of any one of claims 1, 16, 30, 44, 47, 66, or 80, further comprising subjecting the target cells to heat shock.
109. The method of any one of claims 1, 16, 30, 44, 47, 66, or 80, further comprising contacting the target cells with a genotoxic agent and subjecting the target cells to heat shock.
110. The method of any one of claims 1, 16, 30, 44, 47, 66, or 80, wherein said ligand displaying package further comprises an endosomal escape peptide or a cell attachment peptide.
111. The method of claim 110, wherein said endosomal escape peptide or cell attachment peptide is attached to the display package non-covalently.



112. The method of claim 110, wherein said endosomal escape peptide or cell attachment peptide is attached to the display package by a genetic fusion.

113. The method of any one of claims 1, 16, 30, 44, 47, 66, or 80, wherein said bacteriophage displays at least two differing heterologous sequences on its surface.

114. A medicament for gene therapy comprising an internalizing ligand identified by the methods of any one of claims 1, 16, 30, 44, 47, 66, or 80.

115. An anti-bacterial agent comprising an internalizing ligand identified by the methods of any one of claims 1, 16, 30, 44, 47, 66, or 80.

116. A method for identifying transduction facilitating peptides, comprising:

- (a) contacting one or more ligand displaying a genetic packages with a cell(s), wherein each package displays a putative transduction facilitating peptide and a ligand known to internalize, and wherein each package carries a selectable marker which is detectable upon internalization of the package,
- (b) detecting the selectable marker internalized by the cells; and
- (c) recovering a nucleic acid molecule encoding an internalizing ligand from the cell(s) carrying the selectable marker, and  
thereby identifying an internalizing ligand displayed on a genetic package.

1/18




Fig. 1A

2/18







Fig. 1B



3/18

*Fig. 2*


4/18

*Fig. 3A**Fig. 3B*

5/18

Transfection Of COS With FGF Retargeted Phage ( $10^{11}$  pfu/ml)*Fig. 4A*Transfection Of COS With FGF Retargeted Phage ( $10^{11}$  pfu/ml)FGF Competition*Fig. 4B*

6/18

*Fig. 5*

7/18

# Display of High Affinity Ligands on Phage




Fig. 6



8/18

## Optimization of Phage Targeting




Fig. 7

## Optimization of Phage Targeting






Fig. 8

9/18

## Specificity of Phage Targeting

*Fig. 9A*


## Specificity of Phage Targeting

*Fig. 9B*

10/18

# LIVE™ Screening for Target Cells

EGF-Phage transfection of human carcinoma cells



*Fig. 10*

11/18





Fig. 12

12/18


# LIVE<sup>TM</sup> Ligand Selection

Recovery from 1 in a million




*Fig. 11*

13/18

*Fig. 13*

14/18


Effects of Camptothecin and Heat Shock  
Treatments on COS Cell Transduction



*Fig. 14*

15/18

Effects of Endosomal Escape Peptide on  
COS Cell Transduction




*Fig. 15*



16/18

Effects of Heat Shock and Endosomal  
Escape Peptide on Phage Transduction



*Fig. 16*




Fig. 17




Fig. 18

# INTERNATIONAL SEARCH REPORT

Int. .tional Application No  
PCT/US 99/25361

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/10 C12Q1/68 A61K38/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LAROCCA ET AL.: "TARGETING BACTERIOPHAGE TO MAMMALIAN CELL SURFACE RECEPTORS FOR GENE DELIVERY" HUM. GENE THER., vol. 9, 1 November 1998 (1998-11-01), pages 2393-2399, XP000905089 cited in the application the whole document	1-115
X	LAROCCA ET AL.: "TARGETED GENE DELIVERY TO MAMMALIAN CELLS VIA FIBROBLAST GROWTH FACTOR (FGF-2) DISPLAY PHAGE" CANCER GENE THERAPY, vol. 5, no. 6, November 1998 (1998-11), page S10/PD31 XP000905085 the whole document	1-115

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 April 2000

Date of mailing of the international search report

08/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HW Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hagenmaier, S

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/25361

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category	Citation of document, with indication, where appropriate, of the relevant passages	
X	WO 92 20791 A (CAMBRIDGE ANTIBODY TECH ;MEDICAL RES COUNCIL (GB)) 26 November 1992 (1992-11-26) the whole document ---	1-115
X	WO 95 34648 A (DADE INT INC) 21 December 1995 (1995-12-21) the whole document ---	1-115
X	BARRY ET AL.: "Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries" NATURE MEDICINE, US, NATURE PUBLISHING, CO, vol. 2, no. 3, 1 March 1996 (1996-03-01), pages 299-305, XP002086381 ISSN: 1078-8956 cited in the application the whole document ---	1-115
Y	LARocca ET AL.: "TARGETED TRANSDUCTION OF MAMMALIAN CELLS USING A FGF2 MODIFIED FILAMENTOUS BACTERIOPHAGE" CANCER GENE THERAPY, vol. 4, no. 6, 1997, page S24/046 XP000905077 the whole document ---	1-115
Y	HART ET AL.: "CELL BINDING AND INTERNALIZATION BY FILAMENTOUS PHAGE DISPLAYING A CYCLIC ARG-GLY-ASP-CONTAINING PEPTIDE" J.BIOL.CHEM., vol. 269, no. 17, 1994, pages 12468-12474, XP002136134 cited in the application the whole document ---	1-115
Y	SOURIAU ET AL.: "A SIMPLE LUCIFERASE ASSAY FOR SIGNAL TRANSDUCTION ACTIVITY DETECTION OF EPIDERMAL GROWTH FACTOR DISPLAYED ON PHAGE" NAR, vol. 25, no. 8, 1997, pages 1585-1590, XP002136135 the whole document ---	1-115
	---	-/--

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/25361

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category	Citation of document, with indication where appropriate, of the relevant passages	
Y	YOKOYAMA-KOBAYASHI ET AL: "Recombinant f1 phage particles can transfect monkey COS-7 cells by DEAE dextran method" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 192, no. 2, 30 April 1993 (1993-04-30), pages 935-939, XP002086379 ISSN: 0006-291X the whole document	1-115
Y	PASQUALINI R ET AL: "ORGAN TARGETING IN VIVO USING PHAGE DISPLAY PEPTIDE LIBRARIES" NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 380, 28 March 1996 (1996-03-28), pages 364-366, XP002055919 ISSN: 0028-0836 cited in the application the whole document	1-115
Y	DUNN ET AL: "Mammalian cell binding and transfection mediated by surface-modified bacteriophage lambda" BIOCHIMIE,FR,PARIS, vol. 78, no. 10, 1 January 1996 (1996-01-01), pages 856-861, XP002086380 ISSN: 0300-9084 the whole document	1-115
A	WO 98 39482 A (SUNOL MOLECULAR CORP) 11 September 1998 (1998-09-11) the whole document	
A	WO 97 06435 A (MEDICAL RES COUNCIL ;RUSSELL STEPHEN JAMES (GB); MORLING FRANCES J) 20 February 1997 (1997-02-20) the whole document	
P,X	WO 99 10485 A (SELECTIVE GENETICS INC) 4 March 1999 (1999-03-04) the whole document	1-115
P,X	LAROCCA ET AL.: "GENE TRANSFER TO MAMMALIAN CELLS USING GENETICALLY TARGETED FILAMENTOUS BACTERIOPHAGE" FASEB J., vol. 13, April 1999 (1999-04), XP002136137 the whole document	1-115

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/25361

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9220791 A	26-11-1992	AT 145237 T	15-11-1996
		AU 664155 B	09-11-1995
		AU 8221691 A	04-02-1992
		CA 2086936 A	11-01-1992
		DE 69123156 D	19-12-1996
		DE 69123156 T	17-04-1997
		DK 589877 T	07-04-1997
		EP 0589877 A	06-04-1994
		EP 0585287 A	09-03-1994
		EP 0774511 A	21-05-1997
		EP 0844306 A	27-05-1998
		ES 2096655 T	16-03-1997
		WO 9201047 A	23-01-1992
		GR 3022126 T	31-03-1997
		US 5969108 A	19-10-1999
		AT 185601 T	15-10-1999
		AU 665190 B	21-12-1995
		AU 1693892 A	30-12-1992
		CA 2109602 A	26-11-1992
		DE 69230142 D	18-11-1999
		DE 69230142 T	09-03-2000
		JP 6508511 T	29-09-1994
		US 5871907 A	16-02-1999
		AT 181571 T	15-07-1999
		AU 665025 B	14-12-1995
		AU 2593392 A	27-04-1993
		AU 665221 B	21-12-1995
		AU 3089092 A	28-06-1993
		AU 673515 B	14-11-1996
		AU 3763893 A	21-10-1993
		CA 2119930 A	01-04-1993
		CA 2124460 A	10-06-1993
		CA 2131151 A	30-09-1994
		DE 69229477 D	29-07-1999
		DE 69229477 T	09-12-1999
		EP 0605522 A	13-07-1994
		EP 0616640 A	28-09-1994
		EP 0656941 A	14-06-1995
		WO 9306213 A	01-04-1993
		WO 9311236 A	10-06-1993
		WO 9319172 A	30-09-1993
		GR 3031161 T	31-12-1999
		JP 6510671 T	01-12-1994
		JP 7502167 T	09-03-1995
		JP 7505055 T	08-06-1995
		US 5565332 A	15-10-1996
		US 5885793 A	23-03-1999
		US 5733743 A	31-03-1998
		US 5962255 A	05-10-1999
WO 9534648 A	21-12-1995	US 5516637 A	14-05-1996
		AU 697865 B	22-10-1998
		AU 2828295 A	05-01-1996
		CA 2169358 A	21-12-1995
		EP 0722495 A	24-07-1996
WO 9839482 A	11-09-1998	JP 9504181 T	28-04-1997
		AU 6685698 A	22-09-1998

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte. Jonal Application No

PCT/US 99/25361

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9839482 A		EP 0977886 A	09-02-2000
WO 9706435 A	20-02-1997	AU 710446 B	23-09-1999
		AU 6664896 A	05-03-1997
		CA 2225680 A	20-02-1997
		EP 0842426 A	20-05-1998
		JP 11510696 T	21-09-1999
WO 9910485 A	04-03-1999	AU 9039898 A	16-03-1999